# Patent

## Title
Process predicting the value of a phenotypic trait in a plant breeding

## Abstract

Disclosed is a nucleotide sequence comprising substantially the sequence of nucleotides 229 to 2319 of the sequence shown in FIG. 1 encoding an enzyme having exo-(1.fwdarw.4)-.beta.-D-galactanase activity or a precursor or derivative of such an enzyme, or the functional equivalent of such a sequence. Also disclosed are vectors and hosts comprising the sequence of the invention, and a polypeptide encoded thereby. The nucleotide and amino acid sequences of a functionally equivalent enzyme obtainable from tomato fruit are also disclosed.

## Background
This application claims benefit of international application PCT/GB95/00372, filed Feb. 23, 1995.

This invention relates to novel nucleotide sequences and to vectors and hosts comprising said sequences. The invention also relates to a method of altering the characteristics of plants.

Pectin is a major matrix polysaccharide found in the cell wall of plants. Pectins are composed of two distinct regions. The smooth region comprises of long stretches of homogalacturonan interrupted by rhamnose, and is relatively unbranched. The hairy region is rich in galacturonic and rhamnose residues and is highly branched. The side branches contain different sugars but primarily comprise the neutral sugar side chains, arabinan, .beta.-(1.fwdarw.4)-galactan and arabinogalactan. The function of these neutral sugar polysaccnaride side chains has not been fully established. It is speculated that they may function in modulating the pore size of the cell wall and therefore the mobility of proteins, possibly restricting access of various enzymes to their substrates. Moreover, the interaction of the side chains between themselves and with other cell wall polymers could contribute to the structure of the cell wall and the rheoiogical properties of products derived from them. In vitro studies carried out on a solution of apple pectin with different neutral sugar contents demonstrate that increase in branching of pectin results in higher zero-shear viscosity. It was concluded that this was due to pectin side chain interactions. In addition, more branched pectin gives higher elastic or storage moduli (G') than less branched pectin, suggesting that side chain of pectins contribute to elastic properties (Hwang et al., (1993) Food Hydrocolloids 7, 39-53).

The hydrolysis of .beta.-(1.fwdarw.4)-linked galactose from polymeric galactan side chains of pectin has been demonstrated in different plants and in various physiological states (de Vetten and Huber (1990) Physiol. Plant. 78, 447-454; Fischer and Bennett (1991) Ann. Rev. Plant Physiol Plant Mol. Biol. 42, 675-703). During the process of fruit ripening, the loss of the neutral sugar, galactose, is the single most extensive change in the cell walls of many fruits (Fischer and Bennett 1991). Galactose mobilization during fruit ripening has been demonstrated in several fruits including tomato, hot pepper, strawberry, apple, coffee, muskmelon, kiwi fruit, and nectarines. During the senescence of carnation petals, the decrease in cell wall yield is due largely (45%) to a loss of the neutral sugar galactose (de Vetten and Huber 1990). In germinating lupin cotyledons, up to 80% of galactose is mobilized primarily from the .beta.-(1.fwdarw.4)-linked galactan side chains of the rhamnogalacturonan backbone from secondary cell walls adapted to a storage function. A .beta.-galactosidase (exo-(1.fwdarw.4)-.beta.-D-galactanase) would be the enzyme activity predicted to be responsible for galactose mobilization from the galactan side chains of pectin.

.beta.-Galactosidase enzvme activities (including exo-galactanase activities) in plants have been described in the prior art (Dick et al., (1990) Physiol. Plant. 89, 369-375; Burns (1990) Phytochemistry 29, 2425-2429; Singh and Knox. (1985) Phytochemistry 24, 1639-1643; Kundu et al., (1980) Phytochemistry 29, 2079-2082). The purification of some .beta.-galactosidase enzymes has been described, though in many instances synthetic substrates rather than endogenous substrates have been used for enzvme characterization (Ogawa et al., (1990) Nippon Shokuin Kogyo Gakkaishi 37, 298-305; Giannakouros et al., (1991) Physiol. Plant. 82, 413-418). There is evidence that plant .beta.-galactosidases may be associated with developmental processes requiring cell wall turnover, like tissue elongation in Cicer arietinum epicotyl segments. In this tissue, .beta.-galactosidase has been demonstrated to he responsible for autolysis, and the natural substrate of the autolytic reaction is the pectic fraction of the cell wall (Dopico et al., (1989) Physiol. Plant. 75, 458-464; Valero and Labrador (1993) Physiol. Plant. 89, 199-203). A .beta.-galactosidase has been highly purified from the buffer-soluble fraction of carrot cell culture homogenate (Konno et al., (1986) Physiol. Plant. 68, 46-52). The enzyme was active on .beta.-(1.fwdarw.4)-linked galactan prepared from citrus pectin in an exo fashion. The loss of galactose in cell walls during softening has been widely documented (Bartley (1974) Phytochemistry 13, 2107-2111; Redgewell et al., (1992) Plant Physiol. 98, 71-81; Wegrzyn and MacRae (1992) Hort. Sci. 27, 900-902). In tomato, it has been found that the increase in monomeric galactose during fruit ripening is due to an increase in the rate of galactose solubilization from the cell wall rather than changes in the rate of metabolic utilization of the solubilized galactose (Kim et al., (1991) Postharvest Biol. Technol. 1, 67-80). This suggests the action of .beta.-galactosidases in vivo during fruit ripening. There have been several reports of increased .beta.-galactosidase activity during the process of fruit ripening (Bartley 1974; Pressey (1983) Plant Physiol. 71, 132-235; Ross et al., (1993) Planta 1889, 499-506). The .beta.-galactosidase purified from kiwifruit was active in cleaving terminal galactose attached at either the 2, 3, 4 or 6 position (Ross et al., 1993). In tomato fruits, Gross and Wallner (1979, Plant Physiol. 63, 117-120) have shown that decline in wall galactans precedes or accompanies increase in soluble polyuronide. Pressey (1983) has characterized three .beta.-galactosidase activities in ripening tomato fruits of which one (.beta.-galactosidase II), increases 3-fold during ripening. This enzyme was also able to degrade galactan extracted from the cell walls of green tomato and the author suggests a possible role for it in tomato softening. A .beta.-galactosidase has been purified from ripe coffee beans which increases four fold during the transition from immature to ripe fruits (Golden et al., (1993) Phytochemistry 34, 355-360). The enzyme displayed activity against galactan and arabinogalctan, however pectin yielded galactose only in conjunction with an endopolygalacturonase activity.

Solubilization of pectin during fruit ripening is a well-documented phenomenon (Fischer and Bennett, 1991). The action of endopolygalacturonase was considered to be the most likely cause of pectin solubilization, which was thought to be the cause of softening of fruits. Recent studies in transgenic tomato fruits argue against PG being the sole causal agent in the process of fruit softening (Giovannoni et al., (1989) Plant Cell 1, 53-63; Smith et al., (1990) Plant Mol. Biol. 14, 369-379). Recent evidence in fruits with no apparent endo or exo polyalacturonase activity suggests a role for .beta.-galactosidases active on the galactan side chains for the solubilization of pectin (Cutillas-Iturralde el al., (1993) Physiol. Plant. 89, 369-375). Ranawala et al., ((1992) Plant Physiol. 100, 1318-1325) have described a NaCl-released .beta.-galactosidase activity from cell walls of ripe muskmelon (Cucumis melo) fruits, that has the ability to degrade (in vitro) pectin extracted from pre-ripe fruits to smaller sizes of pectin, similar to those observed in ripe fruits. Moreover, there is no detectable PG activity at any stage of muskmelon fruit development and ripening. De Veau et al., (1993 Physiol. Plant. 87, 279-285) have demonstrated increased pectin solubility and decreased apparent molecular weight of pectin extracted from mature green tomato fruits when digested in vitro with .beta.-galactosidases isolated from avocado fruits. Though tomato pectin has been shown to contain at least 10% galactose, only 0.2% was mobilized using avocado derived .beta.-galactosidases. However, this minor change in pectin galactose composition was sufficient to change the solubility of polymeric pectin. These results suggest that an exo-galactanase might play an important role in the pectin solubilization during the process of fruit ripening.

For all the .beta.-galactosidase activities so far described, there are only some indications as to which of the macromolecular components of the cell walls are the actual in vivo substrates. An exception is the .beta.-galactosidase isolated from germinating nasturtium (Tropaeolum majus) cotyledons. The enzyme activity is coincident with xyloglucan mobilization, and the purified enzyme has the unique capability of hydrolysing the terminal .beta.-1,2-linked galactose from the galactoxylosyl sidechain of the xyloglucan polymer (Edwards et al., (1988) J. Biol. Chem. 263, 4333-4337). Buckeridge and Reid recently described (in the printed abstracts of disclosures made at the 6.sup.th Cell Wall Meeting, Nijmegen, Aug. 25-28, 1992, and at the Scottish Cell Wall Group Meeting, April 1993) the purification of a .beta.-galactosidase (an exo-(1.fwdarw.4)-.beta.-D-galactanase) that metabolises the linear .beta.-(1.fwdarw.4)-galactan component of the lupin cotyledonary cell wall. This enzyme is thought to play a key role in the post germinative mobilization of galactan. The enzyme activity is detectable only when galactan mobilization begins, increases during the period of galactan mobilization, and subsequently declines. The changes in exo-galactanase enzyme activity have been shown to correlate with changes in the level of the exo-galactanase enzyme, as determined by immunoblotting. This enzyme is highly specific to .beta.-(1.fwdarw.4)-galactan and does not hydrolyse other plant cell wall polysaccharides known to have terminal non-reducing galactose residues, like nasturtium xyloglucan (terminal (1.fwdarw.2)-.beta.-linked galactose) and larch arabinogalactan (terminal non-reducing (1.fwdarw.3) and (1.fwdarw.6) linked galactose residues.

The enzyme, exo-(1.fwdarw.4)-.beta.-D-galactanase, (which catalyses the hydrolysis of terminal galactose residues from (1.fwdarw.4)-.beta.-linked galactan side chains) appears to have an important role during several physiological processes. The present inventors have achieved the partial protein sequencing, cloning and sequence analysis of a full length cDNA coding for the exo-(1.fwdarw.4)-.beta.-D-galactanase from germinating agricultural lupins (Lupus angustifolius).

In a first aspect the invention provides a nucleotide sequence comprising substantially nucleotides 229 to 2319 of the sequence (Seq ID No. 1) shown in FIG. 1 encoding an enzyme having exo-(1.fwdarw.4)-.beta.-D-galactanase activity, or a precursor or derivative of such an enzyme, or the functional equivalent of such a nucleotide sequence.

For the purposes of the present specification, a precursor shall be understood to mean a polypeptide (active or inactive), which is longer than that encoded by nucleotides 229 to 2319 of the sequence shown in FIG. 1, which can be processed (e.g by proteolysis) in vitro or, more preferably, in vivo, to yield an active enzyme. A derivative shall be understood to mean a polypeptide, obtained by processing in vitro or in vivo, having enzyme activity, which is shorter than that encoded by nucleotides 229 to 2319 of the sequence shown in FIG. 1. Particularly preferred derivatives are those having molecular weights of about 60 kDa and 45 kDa (as determined by SDS-PAGE), which are formed either by intracellular C-terminal cleavage of the polypeptide encoded by nucleotides 229 to 2319 of FIG. 1, or which arise during purification of the enzyme.

Preferably the nucleotide sequence of the invention comprises a 5' ATG start signal. It is also preferred that the sequence further comprises a suitable 5' untranslated region, including a promoter, to enable expression in appropriate host cells. It is also preferred that the sequence comprises signals to optimise expression in appropriate host cells, such as 3' polyadenylation signal to optimise expression in eukaryotes. The sequence of the invention may also comprise a sequence encoding a signal peptide. Particularly preferred embodiments are those sequences which comprise substantially the nucleotide sequence corresponding to nucleotides 163 to 228, or 151 to 228, or 130 to 228 of the sequence shown in FIG. 1.

The term "functional equivalent" as used herein, is intended to refer to those sequences which differ from the precise nucleotide sequence in FIG. 1. In particular, the term refers to; those nucleotide sequences which encode the same amino acid sequence as that encoded by the sequence shown in FIG. 1 but which, by virtue of the degeneracy of the genetic code, possess a different nucleotide sequence; sequences which encode substantially the same polypeptide but wherein there may be one or more conserved amino acid substitutions (i.e. the substitution of one amino acid for another with similar properties). A functionally equivalent sequence will generally encode a polypeptide exhibiting at least 70%, amino acid homology, preferably at least 75%, and more preferably at least 85% amino acid homology with the amino acid sequence encoded by nucleotides 229 to 2319 shown in FIG. 1. Accordingly, preferred functionally equivalent sequences will be able to hybridise with the complement of the sequence shown in FIG. 1 under standard hybridisation conditions (e.g. such as described by Sambrook et al., 1989), but preferably under more stringent conditions.

A particular example of functional equivalents are those sequences which are substantially the antisense equivalent of nucleotides 229 to 2319 of the sequence of FIG. 1. Such sequences are therefore able to hybridise with the sequence shown in FIG. 1. Preferably such antisense equivalents are able to interfere with the expression of the sense sequence, at the DNA and/or mRNA level.

One functional equivalent to the nucleotide sequence of the invention is the nucleotide sequence comprising substantially nucleotides 117 to 2555 of the sequence (Seq ID No. 18) shown in FIG. 5, which encodes a mature exo-galactanase obtainable from tomato fruit. Also included within the scope of the invention are those nucleotide sequences encoding precursors of the mature enzyme, such as nucleotide sequences comprising substantially nucleotides 42 to 2555 of the sequence shown in FIG. 5. It will be apparent to those skilled in the art that other nucleotide sequences may exist which encode substantially the same amino acid sequence as that of the polypeptide shown in FIG. 5 but which, by virtue of the degeneracy of the genetic code, possess a different nucleotide sequence to that shown in FIG. 5. Such obvious variants are to be considered as functional equivalents falling within the scope of the invention.

In a second aspect the invention provides a polypeptide having exo-(1.fwdarw.4)-.beta.-D-galactanase activity and comprising substantially the amino acid sequence encoded by nucleotides 229 to 2319 of the sequence shown in FIG. 1, or a precursor or derivative of such a polypeptide, or a functional equivalent thereof.

A particular functionally equivalent polypeptide is that encoded by nucleotides 117 to 2555 of the sequence shown in FIG. 5, or a precursor or derivative thereof. One such precursor comprises, for example, the polyeptide encoded by nucleotides 42 to 2555 of the sequence shown in FIG. 5.

In a third aspect the invention provides a vector comprising substantially the sequence of nucleotides 229 to 2319 of the sequence shown in FIG. 1, or a functional equivalent thereof. Preferably the vector is capable of directing the expression of a polypeptide having exo-(1.fwdarw.4)-.beta.-D-galactanase activity in an appropriate host, or is capable (directly or indirectly) of interfering with the expression of such a polypeptide.

Transformation techniques for introducing the sequence of the invention into various hosts are well-known to those skilled in the art. Accordingly, in a fourth aspect the invention provides a host or host cell into which the sequence of the invention (or a functional equivalent thereof) has been artificially introduced. Preferably the host or host cell is a plant or plant cell, although other hosts could be employed. For example, if one wished to express large quantities of the enzyme, one could introduce the sequence of the invention into a yeast cell. Possible uses of such a purified, recombinant enzyme include the following: modification, degradation or liquefaction of plant materials in order to affect (a) mechanical properties relating to eating texture; (b) particle sizes of, for example, fruit or vegetable juices (affecting haze); or (c) extractability of colors, flavours or vitamins.

As will be clear to those skilled in the art, because of the role exo-(1.fwdarw.4)-.beta.-D-galactanase plays in breaking down polymers present in the plant cell wall, altering (increasing or decreasing) the levels, or altering the pattern, of expression of this enzyme in a plant might have an effect on certain characteristics of the plant. In particular, one might expect to be able to alter; growth, texture or ripening of the plant or part thereof.

In a fifth aspect, the invention provides a method of altering the characteristics of a plant or part thereof, comprising introducing into the plant the sequence of the invention or a functional equivalent thereof, so as to alter the level or pattern of exo-(1.fwdarw.4)-.beta.-D-galactanase activity in the plant.

If the sequence introduced into the plant is in the sense orientation relative to the promoter, it may result in increased levels of expression. Conversely, introduction into a plant of a sequence in the antisense orientation relative to the promoter may result in a reduction of levels of expression. The plant into which the sequence is introduced is preferably a commercially significant plant in which molecules comprising (1.fwdarw.4)-.beta.-D-linked galactanase residues perform a structural role. Examples of such plants include: alfalfa, apple, broccoli, cabbage, carrot, cauliflower, celery, cranberry, cucumber, eggplant, flax, grape, horseradish, kiwi, lettuce, mangoes, melon, oilseed rape, papaya, pea, peaches, pears, peppers, plum, potato, raspberry, soybean, strawberry, suzarbeat, sweet potato, tobacco, tomato and walnut.

With the knowledge of the sequence data disclosed herein, those skilled in the art will appreciate that it should prove possible to clone functionally equivalent sequences (as defined above) from other plants. Accordingly, in a further aspect the invention provides a method of isolating a functionally equivalent sequence, comprising isolating mRNA from a plant of interest and screening (by means of hybridisation or PCR) the cDNA obtained therefrom using a probe nucleic acid sequence which is substantially complementary to at least part of the sequence shown in FIG. 1.

The invention will now be described by way of example and with reference to the drawings, of which:

FIG. 1 shows the nucleotide sequence (Seq ID No. 1) of the invention together with the amino acid sequence (Seq ID No. 2) of the polypeptide encoded by the nucleotide sequence;

FIG. 2 shows the N-terminal amino acid sequence data obtained by peptide sequencing of the 60, 45 and 15 kDa lupin polypeptides that co-purify during enzyme purification (Seq ID No.s 3-5 respectively);

FIG. 3 shows the N-terminal amino acid sequence data for the 60 kDa lupin exo-galactanase SEQ ID No. 3 together with the nucleotide sequence of EXO1 (Seq ID No. 6), the probe used to screen the cDNA library;

FIG. 4 shows a comparison between the cDNA-encoded polypeptide sequences of lupin exo-galactanase (SEQ ID No. 2) and that encoding a protein of unknown function (SEQ ID No. 20) from carnations (which sequence is already found in publicly available databases);

FIG. 5 shows the cDNA sequence (Seq ID No. 18) of a functionally equivalent enzyme from tomato, together with the amino acid sequence (Seq ID No. 19) of the polypeptide encoded thereby; and

FIG. 6 shows a comparison of the amino acid sequences of the lupin (SEQ ID No. 2) and tomato (SEQ ID No. 19) enzymes; the tomato polypeptide sequence is shown boxed and those portions of the lupin polypeptide which possess an identical sequence are also boxed.

SDS-PAGE and Electroblotting for N-terminal Sequence Analysis:

The lupin exo-galactanase enzyme was purified from 18-days after planting (dap) lupin cotyledons as described (Buckeridge and Reid 1993, abstracts described previously), and supplied by Dr. J. S. Grant Reid (University of Stirling). The protein preparation was composed of a major protein (60 kDa), and two minor proteins (45 kDa and 15 kDa) when analyzed on SDS gels. SDS-PAGE was performed by the method of Laemmli (1970, Nature 227, 680-685) on linear 10% (w/v) acrylamide slab gels on a BioRad electrophoresis kit. Proteins were electroblotted onto the PROBLOTT.TM. membrane (Applied Biosystems, Warrington, U.K.) as described by Matsudaira (1987) with the following adaptations. Gels were pre-run with 50 .mu.M glutathione (Sigma) added to the cathode electrode buffer. Sodium thioglycolate (0.1 mM, Sigma) was added to fresh cathode buffer for sample electrophoresis. Protein was stained with Coomassie brilliant blue following Applied Biosystem's recommendations.

Endoproteinase Lys-C Digestion:

A preparation containing approximately 50 .mu.g purified enzyme (800 pmoles intact exo-galactanase) was brought to pH 8.5, measured with indicator paper, using 1M Tris/HCl pH 8.5. The sample was boiled for 5 min to denature the protein. Endoproteinase Lys-C (Sequencing grade: Boehringer Mannheim) was added at a ratio of 1:50 w/w. The incubation was left at 37.degree. C. overnight and stored at -20.degree. C. prior to reversed-phase chromatography.

HPLC Separation of Peptides:

Reversed-phase chromatography was performed at 30.degree. C. on Applied Biosytems model 130A HPLC separation system. Samples were loaded, via a 500 .mu.l loop onto a Brownlee RP 300-C8 microbore column (250.times.1 mm id: 7.mu.) pre-equilibrated in 0.1% (v/v) TFA. Flow rate was 0.1 ml min.sup.-1. Peptides were eluted with a gradient of increasing buffer B (90% acetonitrile: 0.085% TFA) 0-70% over 70 minutes. Absorbance was monitored at 214 nm and peaks were collected manually into Eppendorf tubes with a time delay to allow for the dead space between the detector and outlet. Fractions were stored at -20.degree. C. Prior to loading sample onto the HPLC, acetonitrile gradients were performed until a reproducible low baseline was obtained.

Protein Sequencing:

This was performed on the Applied Biosystems model 475 protein sequencer.

At the stage of protein purification (18 d.a.p), the exo-galactanase enzyme was purified as a 60 kDa protein, along with a 45 kDa and a 15 kDa protein that co-purifies with it. The N-terminal amino acid sequence of these three polypeptides is illustrated in FIG. 2 (Seq ID No.s 3-5). The Figure shows that the 60 and 45 kDa proteins have an identical N-terminal sequence suggesting that they are derived by C-terminal cleavage of the same parent molecule. Antiserum raised against and affinity purified on the 60 kDa protein recognises larger proteins (.about.80 kDa) at earlier stages of seed germination. It is possible that the purified enzyme (60 kDa) is proteolytically derived from a larger precursor. This is evident from the observation that the deduced protein coded for by the purified cDNA, has a molecular weight of .about.77 kDa. The C-terminal cleavage could occur in vivo or during the process of protein purification. The 60 kDa polypeptide clearly retains activity and is regarded as a functionally equivalent derivative of the sequence of the invention. The 45 kDa polypeptide may possess activity (this has not yet been investigated) and, if so, would also be regarded as a functionally equivalent derivative of the sequence of the invention.

mRNA Isolation and cDNA Library Synthesis:

12 d.a.p lupin cotyledons were supplied by Dr. Reid (Univ of Stirling). Total RNA was extracted using Qiagen columns according to manufacturers recommendations, with some modifications. Total RNA was extracted in two batches. In each batch, 1.5 g of 12 d.a.p lupin cotyledons was ground to a fine powder under liquid nitrogen and distributed to six tubes, each containing 3 mls of cold extraction buffer (4M Guanidine thiocyanate, 100 mM Tris HCl pH7.5, and 25 mM EDTA). To this was added 3 .mu.l of .beta.-mercaptoethanol and 240 .mu.l of 25% Triton X-100 and the mix was incubated on ice for 15 min, 3 mls of cold 3 M Sodium acetate pH6 was added and incubation on ice continued for a further 15 min. The homogenate was centrifuged at 15,000.times.g for 30 min at 4.degree. C. 5 mls of cold iso-propanol was added to the supernatant and incubated on ice for 5 min. The precipitate was concentrated by centrifugation at 15,000.times.g for 30 min at 4.degree. C. The pellet was resuspended in 8 ml of cold TE (20 mM Tris HCl pH8, 1 mM EDTA), and undissolved particles were removed by an additional centrifugation at 20,000.times.g for 15 min at 4.degree. C. 2 ml of S1 (2M NaCl and 250 mM MOPS pH7) was added to the supernatant, which was then applied to a Qiagen-tip 100 column pre-equilibrated with 3 ml of buffer QAT (0.4M NaCl, 50 mM MOPS pH7.0, 15% ethanol and 0.15% Triton X-100). Each column was then washed with 15 ml of buffer QA (0.4M NaCl, 50 mM MOPS pH7.0, and 15% ethanol). Total RNA was eluted with 7.5 ml of buffer QRU (0.9M NaCl, 50 mM MOPS pH7.0, 15% ethanol and 6M Urea), precipitated with an equal volume of iso-propanol for 10 min on ice and centrifuged at 15,000.times.g for 30 min at 4.degree. C. The pellet was washed once in 80% ethanol, air dried and dissolved in a total of 1.5 ml. All the fractions were pooled at this stage and the yield of total RNA quantified spectrophotometrically at O.D.sub.260.

Messenger RNA was fractionated from 1.2 mgs of lupin total RNA by affinity chromatography on oligo(dT) cellulose, using Poly (A.sup.+) Quik columns from Stratagene according to manufacturers instructions, 5 .mu.g of poly (A.sup.+) RNA was used to synthesize a directional cDNA library using a ZAP cDNA synthesis kit (Stratagene) and packaged using Gigapack II Gold.TM. packaging extract (Stratagene) according to manufacturers instructions. The packaged library had a titre of approx 1.times.10.sup.6 pfu of which 4.8.times.10.sup.4 pfu were screened in duplicate.

Design of Oligonucleotide Probe:

A stretch of 8 amino acids (shown underlined and in bold type in FIG. 3a) within the N-terminal peptide sequence of the mature lupin exo-galactanase enzyme was used to design an oligonucleotide probe (EXO1, shown in FIG. 3b, Seq ID No. 6) for the screening of the cDNA library. The oligonucleotide was 23 nucleotides long with a degeneracy of 48 and incorporated one inosine at a wobble base position. The oligonucleotide probe was designed to be complementary to the mRNA coding for the lupin exo-galactanase.

cDNA Library Screening:

Screening of the lupin cDNA library was essentially as described in the ZAP cDNA synthesis and cloning protocol (Stratagene). A total of 4.8.times.10.sup.4 plaque forming units (pfu) were plated on four LB (Luria-Bertani) agar plates, using the Sure.TM. strain of Escherichia coli bacteria (Stratazene), and incubated for 16 h at 39.degree. C. The plates were then chilled for 2 hr at 4.degree. C. and plaque lifts were made in duplicate onto 150 mm nitrocellulose filters (SS) as described (Sambrook et al., (1989) Molecular Cloning, A Laboratory Manual. 2.sup.nd edition, Cold Spring Harbor Laboratory Press). Following denaturation and neutralization, the filters were baked at 80.degree. C. for 2 hrs. The filters were incubated in 30 mls of pre-hybridization solution (6.times.SSC, 5.times. Denhardts, 100 .mu.g/ml salmon testis DNA, and 0.5% SDS) at 42.degree. C. for 4 hrs with gentle agitation, 15 pmol of oligonucleotide EXO1 was end labelled using gamma-.sup.32 -P ATP with polvnucleotide kinase as described (Sambrook et al. 1989). Labelled oligonucleotides were separated from the unincorporated radioactive nucleotides by passage through a P-50 column, and added to the pre-hybridization solution at a concentration of 2.times.10.sup.5 cpm/ml. Hybridization was carried out for 18 hrs with gentle shaking at 42.degree. C., following which the filters were washed briefly (1-2 mins) in two changes of 6.times.SSC, wrapped in saran-wrap, and exposed to x-ray film (Kodak.TM. LS); Autoradiography was carried out for 16 hrs at -80.degree. C. in cassettes with intensifying screens. Positive plaques were identified by autoradiography and the plaques picked into SM. 12 positive clones were taken through an additional round of screening to plaque purity. An estimate of the abundance of the mRNA coding for the lupin exo-galactanase cannot be made based on these results as the probe used (designed to the N-terminal peptide sequence), would be expected to detect only full length cDNAs. Following the second round of screening, 6 plaque pure positives were isolated, and in vivo excised.

In Vivo Excision:

Positive clones were in vivo excised with the Bluescript.TM. phagemid from the Uni-Zap XRT.TM. vector as described in the manufacturers protocol (Stratagene), plasmid preparations of the isolated clones were made using Qiagen P-100 tip columns as recommended by the manufacturer. Clones were further investigated by PCR (polymerase chain reaction) and by restriction analysis, 5 of the 6 isolated clones were successfully amplified using EXO 1 and a vector-based primer for amplification in the PCR. The 5 clones all possessed an insert of similar size (.about.2,600 bp) which was released upon digestion of the purified Bluescript plasmid with the restriction enzymes Eco RI and Xho I, as determined by agarose gel electrophoresis.

Sequence Determination:

The cDNA isolated by screening the lupin cDNA library using the oligonucleotide EXO 1 was analyzed by sequencing the double stranded plasmid using appropriate primers by Taq Dye-Deoxy.TM. terminator chemistry and analyzed on the automated ABI 373A DNA sequencer.

Sequence Analysis:

The isolated cDNA clone (Seq ID No. 1, shown in FIG. 1) is 2628 bp long and includes a 30 bp poly A tail. The longest open reading frame (2190 bp, upper case letters) codes for a 730 amino acid polypeptide (Seq ID No. 2, 81.6 kDa, shown above the nucleotide sequence in single letter code) and includes a 33 amino acid putative signal peptide. However, there are three additional possible start sites between the first start (ATG) codon and the N-terminal of the mature protein which would reduce the signal peptide to either 26, 22 or 15 amino acids. The first three start sites all precede the hydrophobic core that is located within the signal peptide. The mature enzyme is coded for by 697 amino acids with a molecular weight of .about.77 kDa. As previously mentioned, the antibody raised against the .about.60 kDa protein cross reacts with a larger protein (.about.80 kDa), and this might serve as a precursor to the 60 kDa protein by cleavage at the C-terminal end, as the N-terminal sequence of the 60 kDa band and the mature enzyme (deduced from the cDNA) are identical. The serine (underlined) at residue 34 marks the start of the amino acid sequence of the mature protein, the deduced sequence immediately C-terminal of this corresponding to the amino acid sequence actually determined by protein sequencing. The N-terminal of the small (.about.15 kDa) protein has been located within the deduced amino acid of the cDNA, and cleavage at this point would release a 12.5 kDa protein, confirming that this molecule is derived by the cleavage of the C-terminal of the synthesized protein. All the peptide sequences derived by protease digestion and sequencing of the enzyme (peptide sequence data obtained include the following: VAKKQPLAWYKTT, FSAPAGNDPL, GEVWVNGQSIG, and GNCGNCNYAGTYTDTK, Seq ID No.s 7-10 respectively) have been located within the deduced amino acid sequence of the cDNA, further confirming the identity of the cDNA as the one coding for the lupin exo-galactanase. Whether the synthesized enzyme is specifically cleaved in vivo or whether cleavage occurs during the purification process is open to speculation.

Homology to Other Sequences:

The lupin exo-galactanase shows high homology to at least one other sequence. At the amino acid level, it has a 66.5% identity over a 717 amino acid overlap with the deduced amino acid sequence of a highly expressed ethylene regulated gene with unknown function isolated from senescing carnation petals (Raghothama et al., (1991) Plant Mol. Biol. 17, 61-71). This level of amino acid homology is insufficient for the sequence to he considered as a functional equivalent of the lupin exo-galactanase. A comparison between the two polypeptide sequences is shown in FIG. 4, the carnation sequence (CARS12.pro) above the lupin sequence (LEG11CON.pro). Comparison of these two sequences reveals a number of peptides (shown in boxes) which might well be conserved amone enzymes of this type. It is suggested that functional equivalents of lupin exo-galactanase which exhibit a higher degree of homology than that shown by the carnation polypeptide may also comprise these or similar peptide sequences.

Isolation of exo-galactanase cDNAs from Other Plants

With knowledge of the sequence of the exo-galactanse from lupins, it should prove possible for those skilled in the art to isolate functionally equivalent cDNAs from other plants. Described below is a method which could potentially be used for this purpose.

The cDNA coding for the lupin exo-galactanase will be used to isolate functional homologues from other plants (e.g. tomato). The lupin cDNA will be radiolabelled and used as a probe to screen a cDNA library constructed from mRNA isolated from the plant of interest. About 3.times.10.sup.4 pfu will be plated on each LB-agarose plate (as described previously) and filters will be probed with the radiolabelled full-length lupin exo-galactanse cDNA. The hybridisation solution will be as described above, but the temperature of hybridisation will be reduced to about 50.degree. C. The lower temperature is necessary because a heterologous probe (i.e. lupin cDNA) will be used to screen the cDNA library. The hybridised filters will be washed in 2.times.SSC at room temperature for 20 minutes and exposed to x-ray sensitive films. Putative positive clones will be plaque purified and sequence-analysed for homology with the lupin exo-galactanase cDNA. The example below illustrates how this procedure was used to isolate cDNA clones encoding an exo-galactanase from tomato fruits which is functionally equivalent to that obtained from lupin.

Purification of a Polypeptide from Tomato with exo-galactanase Activity

Step 1: Assay for Activity of exogalactanase

Exo-galactanase activity in various tomato fruit extracts was measured by the release of free galactose from galactan isolated from lupin seed. Each assay contained the following components: 30 .mu.l of a 1% galactan solution, 15 .mu.l 1M ammonium acetate pH 5.0 containing 0.1% sodium azide and up to 30 .mu.l tomato extract depending on enzyme activity. Assays were incubated at 30.degree. C. for 17-24 hours and terminated by boiling the solution for 2 min. Aliquots (64 .mu.l) were used for determination of galactose using .beta.-D-galactose dehydrogenase essentially as described by Kurz and Wallenfels (1974. In "Methods of enzymatic analysis", pp1279-1282. Verlag, Chemie, Weinheim).

Step 2: Extraction of exogalactanase from Tomato Pericarp

It was found that exo-galactanase activity could be efficiently extracted from tomato fruit pericarp by 0.2M sodium phosohate buffer, pH 7.2

Step 3: Choice of Starting Material for Purification

Crude extracts were made (in 0.2M sodium phosphate buffer, pH 7.2) from tomato pericarp (Lycopersicum esculentum, var. Moneymaker) tissues taken from various stages of growth and ripening. It was found that pink and red fruit had the highest exogalactanase activity, whether expressed as total or specific activity. Therefore the pericarp of red fruit was used as the starting material for purification.

Step 4: Ammonium Sulphate Precipitation

Pericarp tissue (500 g) from red fruit was harvested, frozen in liquid nitrogen, and stored at -20.degree. C. The tissue was homogenised in 1 g:1.5 vol 0.2M sodium phosphate, pH 7.2 with 1.0% (w/v) insoluble PVP (polyvinyl pyrrolidone) in a blender. The homogenate was stirred for 1 hour at 4.degree. C. to allow diffusion of cell wall enzymes into the extraction buffer. Insoluble material was removed by centrifugation at 20,000.times.g, 10 min. 4.degree. C. in the SS34 rotor of the Sorvall RC5B centrifuge. The supernatant was passed through glasswool, and brought to 30% ammonium sulphate saturation by addition of solid ammonium sulphate (16.4 g/100 ml). The mixture was stirred for 40 min at 4.degree. C., and the precipitated proteins were removed by centrifugation (30,000.times.g, 20 min, 4.degree. C.). The supernatant was brought to 70% ammonium sulphate saturation by addition of solid ammonium sulphate (24.9 g/100 ml). The mixture was stirred for 40 min at 4.degree. C., and the precipitated proteins collected by centrifugation (30,000.times.g, 20 min, 4.degree. C.). The ammonium suldhate precipitated proteins were stored at -20.degree. C. without resuspension.

Step 5: DE52 Chromatography

30-70% ammonium sulphate precipitated proteins were resuspended in 48 ml of 20 mM Tris/HCl, pH 7.8 (Buffer A) and dialysed overnight against 4.5 L of Buffer A. The sample was centrifuged at 30,000.times.g for 10 min, 4.degree. C. and loaded onto a 40 ml DE52 column (Whatman), equilibrated in Buffer A. at 0.5 ml/min. The column was washed with Buffer A (flow rate 1.0 ml/min) until all unbound proteins were removed. Bound proteins were eluted with a 0-100% gradient of Buffer B (as Buffer A. but with 1M NaCl) over 6 column volumes. Fractions (2 ml ) were collected and assayed for exo-galactanase activity. Fractions containing high exo-galactanase activity were either dialysed immediately as detailed below or stored at -20.degree. C.

Step 6: Mono P Chromatography

Fractions pooled from DE52 chromatography were dialysed overnight against 4.5 L of 0.025M triethanolamine/iminodiacetic acid pH 8.3 (Buffer C). The dialysed sample was centrifuged and the supernatant loaded via a 50 ml superloop onto a Mono P column (Pharmacia HR 5/20), equilibrated in Buffer C, at a flow rate of 1 ml/min. The column was washed in Buffer C until all unbound proteins were removed. Bound proteins were eluted from the column with 50 ml 10% (v/v) polybuffer 7/4, pH 4.8/iminodiacetic acid, at a flow rate of 1 ml/min. Fractions (0.5 ml) were collected and assayed for exo-galactanase activity. Fractions containing activity which eluted early in the pH gradient (approx pH 8.0) were pooled and dialysed overnight against 50 mM ammonium acetate pH 5.0 (Buffer D).

Step 7: Lactose Agarose Chromatography

Dialysed sample was loaded onto a 5 ml lactose agarose (Sigma) column, equilibrated in Buffer D, at a flow rate of 0.13 ml/min. The column was washed with Buffer D to remove unbound proteins. Bound proteins were eluted from the column with 0.1M Tris/HCl pH 8.6/0.2M NaCl. Fractions (0.5 ml) were collected and assayed for exo-galactanase activity.

Step 8: N-terminal amino acid Sequencing

Fractions from the lactose agarose column with high exo-galactanase activity were pooled, concentrated 16-fold using a centricon 10 (Amicon), and separated according to apparent molecular weight on a 12.5% SDS polyacrylamide gel. After electrophoresis, proteins were transferred onto a ProBlott membrane (transfer buffer 10 mM CAPS pH 11 in 10% methanol). The ProBlott membrane was stained in 0.1% Coomassie Brilliant Blue R250 in 1% acetic acid, 40% methanol and destained in 50% methanol. Several protein bands were visible. Two bands, of approximate molecular weight 40 kDa and 80 kDa, in fractions coincident with exo-galactanase activity, were excised and subjected to N-terminal amino acid sequencing on an ABI model 475 protein sequencer.

The 80 kDa tomato polypeptide was identified as an exogalactanase by its homology to the lupin enzyme.

80 kDa Tomato polypeptide: SVSYDDRAI* * NG*R (Seq ID No. 11) Lupin Exo-galactanase: SVTYDHKAIMINGQR . . . etc (SEQ ID No. 3) (*=unassigned amino acid)

The identity of the 40 kDa protein is unknown: 40 kDa Tomato polypeptide: FSNNNFVATDGTHFALNGKS (Seq ID No. 12)

The retention of exo-galactanase activity is highly dependent on ionic strength, and activity can be lost if the ionic strength of chromatography buffers etc. is less than 100 mM. An improved purification procedure would be to include 100 mM NaCl (minimum) in all chromatography buffers. The above protocol would need re-evaluation and optimisation to realise the same purification but yield of exo-galactanase protein and activity should be enhanced.

Isolation of Partial cDNA Clones Encoding Tomato exo-galactanase

Using a heterologous cDNA probe (2628 bp) coding for lupin exo-galactanase and a hybridization temperature of 55.degree. C., 2 partial cDNA clones, TEG13 (1082 bp) and TEG6 (415 bp), were isolated from a commercial tomato fruit (breaker stage) cDNA library obtained from Clontech Laboratories Inc. [prepared using mRNA from ripening (breaker stage) fruit (Ailsa craig cultivar VFN8), primed with oligo-(dT) and random primers and cloned into lambda gt11]. Approximately 300,000 cDNA clones from this library were screened using a .sup.32 P-dCTP (Amersham International plc) radiolabelled probe prepared using a kit supplied by United States Biochemicals Inc. (Sequenase v2.0). Unincorporated nucleotides were removed by chromatography through a Sephadex G-50 column. Both clones TEG13 and TEG6 were PCR amplified using TAQ polymerase and lambda gt11 specific primers (GT11 5'B: ACTCCTGGATCCCGTCAGTAT. Seq ID No. 13; and GT11 3'K: TAATGGTACCGACCGGCGCTCT. Seq ID No. 14) cloned into pT7 Blue PCR cloning vector (AMS Biotechnology Limited) and transformed into competent E. coli, according to the manufacturer's instructions. Colonies containing recombinant plasmids were used to inoculate 30 ml Lennox Broth containing 100 .mu.g/.mu.l Carbenicillin: after overnight growth at 37.degree. C., plasmid DNA was purified using a Qiagen plasmid DNA extraction kit, PEG precipitated and washed thoroughly with 70% EtOH.

DNA sequence data were obtained using an automated ABI sequencer, and analysed using an Apple Mac computer and DNAstar software. TEG13 exhibited 64.2% homology with nucleotides 678 to 1760 of the lupin exo-galactanase sequence. TEG6 exhibited 62.7% homology with nucleotides 2014 to 2428 of the lupin exo-galactanase sequence.

Isolation of an Overlapping cDNA Fragment

Because the cDNA clones TEG13 and TEG6 aligned with discreet regions of the lupin exo-galactanase cDNA, a RACE procedure was performed (according to Frohman M, Rapid amplification of cDNA ends (RACE): User friendly cDNA cloning, Amplifications: A forum for PCR users, pp 11-14) in order to obtain an overlapping cDNA fragment (5' extension of TEG6). A 5' cDNA pool was prepared by reverse transcription of tomato fruit (breaker stage) total RNA with MuMLV-RT and random hexanucleotide primers, and subsequent tailing with terminal deoxy-transferase (BRL) in the presence of dATP. In a first round PCR amplification of the 5' cDNA pool, the primer 6A1 (position 84-64 in TEG6 and 1844-1824 in FIG. 5) was used in combination with an outer adaptor primer (R.sub.0 : AAGGATCCGTCGACATC, Seq ID No. 15) and ((dT).sub.17 -R.sub.i -R.sub.0 : AAGGATCCGTCGACATCGATAATACGACTCA CTATAGGGATTTTTTTTTTTTTTTTT, Seq ID No. 16) which annealed to the 5' tail of the cDNA. In a second round of PCR amplification, the primer 6A3 (position 42-22 in TEG6 and 1802-1782 in FIG. 5) was used in combination with a nested inner adaptor primer (R.sub.i : GACATCGATAATACGAC, Seq. ID No. 17), again annealing to the 5' tail of the cDNA. A RACE product of 511 bp was obtained, extending 469 bp beyond the 5' end of TEG6. This treatment was cloned into pT7 and sequenced. The sequence data revealed that the 5' 209 bp of the RACE product was 100% homologous to the 3' end of TEG13, suggesting that TEG13 and TEG6 were 2 partial cDNA clones representing the same gene (TEG1). A homology of 59.2% was found between this overlapping RACE product (TEG7) and nucleotides 1544-2054 of lupin exo-galactanase.

All DNA alignments were calculated using a DNAStar Megalign program (multiple alignment using the Clustal method. Gap penalty: 10, Gap length penalty: 10).

By overlapping the sequences of TEG13, TEG7 and TEG6, a hybrid cDNA molecule of 1757 bp length, containing a continuous open reading frame, is formed. The encoded polypeptide exhibits 68.1% identity to amino acids 135 to 717 of lupin exo-galactanase.

In order to obtain the sequence information at the 5' end of this clone, 3 subsequent RACE experiments were performed on the 5' tomato cDNA pool (5 .mu.l).

1st 5' RACE

In the first round of PCR amplification, the primer 13A2 (position 106-86 in TEG13 and 524-504 in FIG. 5) was used in combination with the outer adaptor primer (R.sub.0) to amplify sequences from the 5' cDNA pool. In the second round of PCR, the primer 13A5 (position 62-42 in TEG13 and 480-460 in FIG. 5) was used in combination with the inner adaptor primer (R.sub.i). A specific fragment of 214 bp was recovered from a 0.8% agarose gel using DEAE paper, cloned into plasmid pT7 and transformed into competent E. coli. The resultant clone was called 5'TEG1.1 and had a 62 bp overlap with the hybrid cDNA molecule, extending the sequence to 1909 bp.

2nd 5' RACE

2 new primers, 1A1 (position 28-8 in 5'TEG1.1 and 294-274 in FIG. 5) and 1A2 (position 63-43 in 5'TEG1.1 and 329-309 in FIG. 5) were designed for use in a second RACE experiment. Primer 1A2 was used in the first round of amplification of the 5' cDNA pool and primer 1A1 in the second round of amplification, in combination with R.sub.0 and R.sub.i respectively. A fragment of 206 bp, was obtained, purified, cloned and sequenced as described above. The clone was called 5'TEG1.2 and had a 26 bp overlap with the extended hybrid cDNA molecule, further extending the sequence to 2089 bp. The 5' end of the extended sequence encoded the C terminal 10 amino acids of a signal peptide followed by the mature N-terminus of tomato exo-galactanase (11/12 amino acids conserved with the N-terminus of purified tomato exogalactanase described above).

3rd 5' RACE

In order to obtain sequence encoding a complete signal peptide, 2 further primers, 1A6 (position 52-32 in 5'TEG1.2 and 138-118 in FIG. 5) and 1A7 (position 32-12 in 5'TEG1.2 and 118-98 in FIG. 5) were synthezised. Primer 1A6 was used in a first round of amplification and primer 1A7 in the second round, as described above. A cDNA product of 117 bp was obtained, purified, cloned and sequenced as above. The clone was called 5'TEG1.3 and had a 32 bp overlap with the extended hybrid cDNA molecule, further extending the sequence to 2175 bp. The extended sequence encoded a complete signal peptide of 25 aa.

3' RACE

In order to obtain a cDNA molecule corresponding to the 3' end of the TEG1 gene, a RACE experiment was carried out on a 3'cDNA pool derived from reverse transcription of tomato fruit (breaker stage) total RNA with MuMLV-RT and the (dT).sub.17 -R.sub.i -R.sub.0 primer. The primer 6S2 (position 340-360 in TEG6 and 2100-2120 in FIG. 5) was used in the first PCR reaction, in combination with R.sub.0 and the primer 6S3 (position 373-393 in TEG6 and 2133-2153 in FIG. 5) in the second (nested) PCR reaction, in combination with R.sub.i. The resultant RACE product was 812 bp long and had a 43 bp overlap with the extended hybrid cDNA molecule, further extending the sequence to 2944 bp, including 23 "A"s ("T"s) at the 3' end.

The complete TEG1 cDNA sequence (Seq ID No. 18) is shown in FIG. 5 and was found to contain a 2514 bp long open reading frame (nucleotide 42 to 2555) encoding a polypeptide (Seq ID No. 19) of 838 amino acids. The signal sequence cleavage site is marked with an arrow. The mature exo-galactanase protein encoded by TEG1 (minus a 25 amino acid signal peptide) is 813 amino acids in length, has a molecular weight of 90.623 daltons and exhibits 70% homology (Lipman-Pearson algorithum, gap penalty: 4. K tuple: 2. length: 12) with the mature exo-galactanase protein encoded by the lupin cDNA and may therefore be regarded as functionally equivalent to the lupin enzyme.

In FIG. 5, nucleotide 1445 is shown as a Y (IUPAC code) whilst in Seq. ID No. 18 in the sequence listing the nucleotide is shown as T. This is purely for convenience: the precise identity of the nucleotide is uncertain. It will be appreciated that, as the nucleotide is at position 3 of a codon, its precise identity is not critical. It will further be noted that the deduced amino acid sequence of the polypeptide encoded by TEG1 differs slightly from the N-terminal sequence of the purified polypeptide as determined by peptide sequencing. Presumably there are a number (at least two) of related genes (e.g. allelic variants) in tomato plants which encode functionally equivalent enzymes having sliohtly different amino acid sequences.

FIG. 6 shows a comparison of the full length amino acid sequences of the lupin enzyme (LEG11CON.pro) and the tomato enzyme (CONTIG.TEG1.PRO). The tomato sequence is shown boxed, and the boxed regions include those portions of the lupin enzyme where the sequence is identical to that of the tomato enzyme. It will be observed that there are several portions of extensive homology (e.g. tomato residues 120-138 & lupin residues 128-146; tomato residues 396-408 & lupin residues 404-416) which may be important to the catalytic function of the molecules.

Construction of Plant Transformation Vectors for Antisense Experiments.

In order to assess the phenotypic consequences of down regulating the expression of TEG1 in transgenic plants, plant transformation vectors were constructed for antisense experiments. The vectors were transferred into Agrobacterium tumefaciens LBA4404. Tomato cotyledons (variety "Moneymaker") were infected with A. tumefaciens carrying the vectors.

The vector p35S/TEG1A was constructed by inserting a 1082 bp SstI/XbaI fragment of TEG1 (419-1500) in the antisense orientation between the constitutive 35S promoter and the nos ployadenylation signal of pKan35S.

The vector p35S/TEG1B was constructed by inserting a 511 bp SstI/XbaI fragment of TEG1 (1292-1802) in the antisense orientation between the constitutive 35S promoter and the nos ployadenylation site of DKan35S.

The vector pKan35S was constructed by inserting a 0.8 kb HindIII-Xba fragment, containing a 35S cauliflower mosaic virus constitutive promoter (from the vector pcTAK, which vector is described by Toepfer et al., 1987 NAR 15. 5890 et seq.), behind the nos poly-adenylation site of pGPTV-kan (Becker et al., 1992 Plant Molecular Biology 20, 1195-1197).

The vector pPG/TEG1A was constructed by inserting a 1082 bp PstI/Blunt/SstI fragment of TEG1 (419-1500) in the antisense orientation between a fruit-specific (-942 to +33) PG promoter (Bird et al., 1988 Plant Molecular Biology 11, 651-662) and the nos ployadenylation site of pGPTV-kan. #             SEQUENCE LISTING - -  - - (1) GENERAL INFORMATION: - -    (iii) NUMBER OF SEQUENCES: 20 - -  - - (2) INFORMATION FOR SEQ ID NO: 1: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2628 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: cDNA - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:130..2319 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #1: - - CAACACTCTT ATACAATAAG AGACTCTCAA AAAGTAGCAA AATAAAAAGA CA - #CTATATAC     60 - - AAAACAGAAA ATATTTCTTC TTCTATAGAA AGACAACATT GCTTATATAG AA - #ACATAGCA    120 - - TTTTTTGTT ATG TTT GGT TCA AGA ATT GTG ATG GAG - # AGT TTA ATG TCT 168 Met Phe Gly Ser Arg - #Ile Val Met Glu Ser Leu Met Ser 1      - #         5         - #         10 - - AGG AGA AAT TTT CAT ATG GTG TTG CTG TTA TT - #G TTT TTT TGG GTT TGT 216 Arg Arg Asn Phe His Met Val Leu Leu Leu Le - #u Phe Phe Trp Val Cys 15             - #     20             - #     25 - - TAT GTC ACA GCC TCT GTT ACT TAT GAT CAT AA - #A GCC ATT ATG ATT AAT 264 Tyr Val Thr Ala Ser Val Thr Tyr Asp His Ly - #s Ala Ile Met Ile Asn 30                 - # 35                 - # 40                 - # 45 - - GGG CAG AGA AGA ATT TTG ATC TCT GGT TCC AT - #T CAC TAT CCA AGA AGC 312 Gly Gln Arg Arg Ile Leu Ile Ser Gly Ser Il - #e His Tyr Pro Arg Ser 50 - #                 55 - #                 60 - - ACA CCT CAG ATG TGG CCA GAC CTT ATT CAA AA - #G GCC AAA GAT GGA GGG 360 Thr Pro Gln Met Trp Pro Asp Leu Ile Gln Ly - #s Ala Lys Asp Gly Gly 65     - #             70     - #             75 - - CTT GAT GTT ATA GAG ACT TAT GTG TTC TGG AA - #T GGA CAT GAA CCT TCT 408 Leu Asp Val Ile Glu Thr Tyr Val Phe Trp As - #n Gly His Glu Pro Ser 80         - #         85         - #         90 - - CCT GGA AAA TAT TAT TTT GAG GAT AGG TTT GA - #C CTT GTT GGG TTC ATA 456 Pro Gly Lys Tyr Tyr Phe Glu Asp Arg Phe As - #p Leu Val Gly Phe Ile 95             - #    100             - #    105 - - AAG TTG GTT CAG CAA GCT GGT CTA TTT GTT CA - #T CTC AGG ATT GGT CCT 504 Lys Leu Val Gln Gln Ala Gly Leu Phe Val Hi - #s Leu Arg Ile Gly Pro 110                 1 - #15                 1 - #20                 1 - #25 - - TTC ATA TGT GCT GAA TGG AAC TTT GGA GGA TT - #T CCT GTT TGG CTC AAA      552 Phe Ile Cys Ala Glu Trp Asn Phe Gly Gly Ph - #e Pro Val Trp Leu Lys 130  - #               135  - #               140 - - TAT GTT CCT GGT ATT GCT TTC AGA ACA GAC AA - #T GAG CCT TTC AAG GAG 600 Tyr Val Pro Gly Ile Ala Phe Arg Thr Asp As - #n Glu Pro Phe Lys Glu 145      - #           150      - #           155 - - GCA ATG CAA AAA TTC ACT GAG AAG ATT GTA AA - #T ATA ATG AAA GCA GAG 648 Ala Met Gln Lys Phe Thr Glu Lys Ile Val As - #n Ile Met Lys Ala Glu 160          - #       165          - #       170 - - AAG TTG TTT CAA TCC CAG GGA GGT CCA ATA AT - #T CTG TCT CAG ATA GAG 696 Lys Leu Phe Gln Ser Gln Gly Gly Pro Ile Il - #e Leu Ser Gln Ile Glu 175              - #   180              - #   185 - - AAT GAG TAT GGA CCA GTG GAA TGG GAA ATT GG - #T GCT CCT GGA AAA GCT 744 Asn Glu Tyr Gly Pro Val Glu Trp Glu Ile Gl - #y Ala Pro Gly Lys Ala 190                 1 - #95                 2 - #00                 2 - #05 - - TAT ACC AAA TGG GCT GCT CAA ATG GCT GTA GG - #T CTA GAT ACT GGT GTC      792 Tyr Thr Lys Trp Ala Ala Gln Met Ala Val Gl - #y Leu Asp Thr Gly Val 210  - #               215  - #               220 - - CCA TGG GTT ATG TGC AAG CAA GAA GAT GCA CT - #T GAT CCT ATT ATT GAT 840 Pro Trp Val Met Cys Lys Gln Glu Asp Ala Le - #u Asp Pro Ile Ile Asp 225      - #           230      - #           235 - - ACC TGC AAT GGA TTT TAC TGT GAA AAC TTC AC - #T CCA AAC AAG AAC TAC 888 Thr Cys Asn Gly Phe Tyr Cys Glu Asn Phe Th - #r Pro Asn Lys Asn Tyr 240          - #       245          - #       250 - - AAA CCC AAA TTG TGG ACA GAA AAT TGG ACT GG - #C TGG TAC ACT GCT TTT 936 Lys Pro Lys Leu Trp Thr Glu Asn Trp Thr Gl - #y Trp Tyr Thr Ala Phe 255              - #   260              - #   265 - - GGT GGT GCA ACC CCT TAT AGA CCA GCA GAA GA - #T ATA GCA TTT TCA GTT 984 Gly Gly Ala Thr Pro Tyr Arg Pro Ala Glu As - #p Ile Ala Phe Ser Val 270                 2 - #75                 2 - #80                 2 - #85 - - GCC AGA TTC ATT CAG AAT CGC GGC TCA CTC TT - #T AAC TAC TAT ATG TAT     1032 Ala Arg Phe Ile Gln Asn Arg Gly Ser Leu Ph - #e Asn Tyr Tyr Met Tyr 290  - #               295  - #               300 - - CAT GGA GGA ACT AAC TTT GGC CGG ACA TCG AA - #T GGC CTC TTC GTT GCC 1080 His Gly Gly Thr Asn Phe Gly Arg Thr Ser As - #n Gly Leu Phe Val Ala 305      - #           310      - #           315 - - ACA AGT TAT GAC TAT GAT GCT CCC ATT GAT GA - #A TAT GGA CTT CTA AAT 1128 Thr Ser Tyr Asp Tyr Asp Ala Pro Ile Asp Gl - #u Tyr Gly Leu Leu Asn 320          - #       325          - #       330 - - GAA CCA AAA TGG GGG CAT CTG AGA GAA TTA CA - #T AGA GCA ATA AAA CAA 1176 Glu Pro Lys Trp Gly His Leu Arg Glu Leu Hi - #s Arg Ala Ile Lys Gln 335              - #   340              - #   345 - - TGC GAG TCG GCT TTA GTG TCG GTG GAT CCC AC - #A GTG TCA TGG CCT GGA 1224 Cys Glu Ser Ala Leu Val Ser Val Asp Pro Th - #r Val Ser Trp Pro Gly 350                 3 - #55                 3 - #60                 3 - #65 - - AAA AAC CTT GAG GTA CAT TTG TAC AAG ACA GA - #G TCT GCC TGT GCT GCA     1272 Lys Asn Leu Glu Val His Leu Tyr Lys Thr Gl - #u Ser Ala Cys Ala Ala 370  - #               375  - #               380 - - TTT CTT GCA AAT TAT AAC ACC GAC TAT TCA AC - #G CAA GTT AAA TTC GGA 1320 Phe Leu Ala Asn Tyr Asn Thr Asp Tyr Ser Th - #r Gln Val Lys Phe Gly 385      - #           390      - #           395 - - AAT GGA CAA TAT GAT CTA CCA CCT TGG TCT AT - #C AGT ATT CTT CCT GAC 1368 Asn Gly Gln Tyr Asp Leu Pro Pro Trp Ser Il - #e Ser Ile Leu Pro Asp 400          - #       405          - #       410 - - TGC AAA ACT GAA GTT TTC AAC ACT GCA AAG GT - #T AAT TCC CCG AGA TTA 1416 Cys Lys Thr Glu Val Phe Asn Thr Ala Lys Va - #l Asn Ser Pro Arg Leu 415              - #   420              - #   425 - - CAT AGG AAA ATG ACT CCA GTA AAC AGT GCA TT - #T GCT TGG CAG TCA TAC 1464 His Arg Lys Met Thr Pro Val Asn Ser Ala Ph - #e Ala Trp Gln Ser Tyr 430                 4 - #35                 4 - #40                 4 - #45 - - AAT GAA GAA CCT GCA TCA TCA AGC GAA AAT GA - #T CCC GTC ACA GGA TAT     1512 Asn Glu Glu Pro Ala Ser Ser Ser Glu Asn As - #p Pro Val Thr Gly Tyr 450  - #               455  - #               460 - - GCA CTA TGG GAG CAG GTT GGC GTG ACC CGC GA - #T TCT TCC GAT TAT TTG 1560 Ala Leu Trp Glu Gln Val Gly Val Thr Arg As - #p Ser Ser Asp Tyr Leu 465      - #           470      - #           475 - - TGG TAC CTG ACA GAT GTC AAC ATT GGT CCT AA - #T GAT ATA AAG GAT GGG 1608 Trp Tyr Leu Thr Asp Val Asn Ile Gly Pro As - #n Asp Ile Lys Asp Gly 480          - #       485          - #       490 - - AAA TGG CCT GTT CTG ACA GCA ATG TCA GCA GG - #T CAT GTT CTG AAT GTT 1656 Lys Trp Pro Val Leu Thr Ala Met Ser Ala Gl - #y His Val Leu Asn Val 495              - #   500              - #   505 - - TTC ATC AAT GGT CAA TAT GCA GGA ACT GCA TA - #T GGG AGT CTA GAT GAT 1704 Phe Ile Asn Gly Gln Tyr Ala Gly Thr Ala Ty - #r Gly Ser Leu Asp Asp 510                 5 - #15                 5 - #20                 5 - #25 - - CCT AGA TTA ACA TTT AGT CAA AGT GTG AAT CT - #G AGA GTT GGC AAT AAC     1752 Pro Arg Leu Thr Phe Ser Gln Ser Val Asn Le - #u Arg Val Gly Asn Asn 530  - #               535  - #               540 - - AAG ATT TCT TTA CTT AGT GTT TCC GTT GGT CT - #C GCG AAT GTT GGT ACT 1800 Lys Ile Ser Leu Leu Ser Val Ser Val Gly Le - #u Ala Asn Val Gly Thr 545      - #           550      - #           555 - - CAC TTT GAG ACA TGG AAT ACT GGA GTG CTT GG - #T CCA GTC ACA CTG ACA 1848 His Phe Glu Thr Trp Asn Thr Gly Val Leu Gl - #y Pro Val Thr Leu Thr 560          - #       565          - #       570 - - GGT CTA AGT AGC GGA ACA TGG GAT CTT TCG AA - #G CAA AAA TGG TCT TAC 1896 Gly Leu Ser Ser Gly Thr Trp Asp Leu Ser Ly - #s Gln Lys Trp Ser Tyr 575              - #   580              - #   585 - - AAG ATT GGT CTG AAA GGT GAA AGC TTG AGC CT - #T CAT ACT GAA GCT GGG 1944 Lys Ile Gly Leu Lys Gly Glu Ser Leu Ser Le - #u His Thr Glu Ala Gly 590                 5 - #95                 6 - #00                 6 - #05 - - AGT AAC TCT GTT GAA TGG GTA CAA GGA TCT TT - #A GTG GCT AAA AAA CAA     1992 Ser Asn Ser Val Glu Trp Val Gln Gly Ser Le - #u Val Ala Lys Lys Gln 610  - #               615  - #               620 - - CCT TTG GCA TGG TAT AAG ACA ACT TTT AGC GC - #A CCA GCC GGC AAC GAT 2040 Pro Leu Ala Trp Tyr Lys Thr Thr Phe Ser Al - #a Pro Ala Gly Asn Asp 625      - #           630      - #           635 - - CCG TTG GCT CTG GAT TTA GGT AGC ATG GGT AA - #G GGT GAA GTA TGG GTA 2088 Pro Leu Ala Leu Asp Leu Gly Ser Met Gly Ly - #s Gly Glu Val Trp Val 640          - #       645          - #       650 - - AAT GGT CAA AGC ATT GGA CGC CAT TGG CCT GG - #A AAT AAA GCT CGT GGT 2136 Asn Gly Gln Ser Ile Gly Arg His Trp Pro Gl - #y Asn Lys Ala Arg Gly 655              - #   660              - #   665 - - AAT TGC GGC AAT TGT AAT TAC GCT GGA ACT TA - #T ACC GAT ACA AAA TGC 2184 Asn Cys Gly Asn Cys Asn Tyr Ala Gly Thr Ty - #r Thr Asp Thr Lys Cys 670                 6 - #75                 6 - #80                 6 - #85 - - TTA GCA AAC TGT GGA CAA CCC TCC CAA AGA TG - #G TAT CAT GTT CCT CGG     2232 Leu Ala Asn Cys Gly Gln Pro Ser Gln Arg Tr - #p Tyr His Val Pro Arg 690  - #               695  - #               700 - - TCA TGG CTG AGA TCG GGT GGT AAC TAC TTG GT - #T GTG CTA GAA GAA TGG 2280 Ser Trp Leu Arg Ser Gly Gly Asn Tyr Leu Va - #l Val Leu Glu Glu Trp 705      - #           710      - #           715 - - GGA GGT GAT CCT AAT GGA ATT GCT TTG GTG GA - #A AGA ACA TAAAGTGTAT 2329 Gly Gly Asp Pro Asn Gly Ile Ala Leu Val Gl - #u Arg Thr 720          - #       725          - #       730 - - TCATGTGATA CCAAATGTAC ATGTTATGTA CATAGTGAAA CTATTATGCT GA - #ATATTGTT   2389 - - CCATATACTA CATTACAGGG TTTGTGTCAC AATGAACATT GAGTCCTTAA AC - #ATTGGTAT   2449 - - AGAAGGGAAA GAGTTGAATA CCCAAAATGG GTCAAAATAC TACATTGTCC TA - #GAAATAGA   2509 - - TTTCTTTCAT TTTCTATATC AACTATTATG TAAGAACAAA TTGAAAGTAA TA - #CTAATAAA   2569 - - TAGTGATGCA TTTGGATTAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA - #AAAAAAA    2628 - -  - - (2) INFORMATION FOR SEQ ID NO: 2: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 730 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #2: - - Met Phe Gly Ser Arg Ile Val Met Glu Ser Le - #u Met Ser Arg Arg Asn 1               5 - #                 10 - #                 15 - - Phe His Met Val Leu Leu Leu Leu Phe Phe Tr - #p Val Cys Tyr Val Thr 20     - #             25     - #             30 - - Ala Ser Val Thr Tyr Asp His Lys Ala Ile Me - #t Ile Asn Gly Gln Arg 35         - #         40         - #         45 - - Arg Ile Leu Ile Ser Gly Ser Ile His Tyr Pr - #o Arg Ser Thr Pro Gln 50             - #     55             - #     60 - - Met Trp Pro Asp Leu Ile Gln Lys Ala Lys As - #p Gly Gly Leu Asp Val 65                 - # 70                 - # 75                 - # 80 - - Ile Glu Thr Tyr Val Phe Trp Asn Gly His Gl - #u Pro Ser Pro Gly Lys 85 - #                 90 - #                 95 - - Tyr Tyr Phe Glu Asp Arg Phe Asp Leu Val Gl - #y Phe Ile Lys Leu Val 100      - #           105      - #           110 - - Gln Gln Ala Gly Leu Phe Val His Leu Arg Il - #e Gly Pro Phe Ile Cys 115          - #       120          - #       125 - - Ala Glu Trp Asn Phe Gly Gly Phe Pro Val Tr - #p Leu Lys Tyr Val Pro 130              - #   135              - #   140 - - Gly Ile Ala Phe Arg Thr Asp Asn Glu Pro Ph - #e Lys Glu Ala Met Gln 145                 1 - #50                 1 - #55                 1 - #60 - - Lys Phe Thr Glu Lys Ile Val Asn Ile Met Ly - #s Ala Glu Lys Leu Phe 165  - #               170  - #               175 - - Gln Ser Gln Gly Gly Pro Ile Ile Leu Ser Gl - #n Ile Glu Asn Glu Tyr 180      - #           185      - #           190 - - Gly Pro Val Glu Trp Glu Ile Gly Ala Pro Gl - #y Lys Ala Tyr Thr Lys 195          - #       200          - #       205 - - Trp Ala Ala Gln Met Ala Val Gly Leu Asp Th - #r Gly Val Pro Trp Val 210              - #   215              - #   220 - - Met Cys Lys Gln Glu Asp Ala Leu Asp Pro Il - #e Ile Asp Thr Cys Asn 225                 2 - #30                 2 - #35                 2 - #40 - - Gly Phe Tyr Cys Glu Asn Phe Thr Pro Asn Ly - #s Asn Tyr Lys Pro Lys 245  - #               250  - #               255 - - Leu Trp Thr Glu Asn Trp Thr Gly Trp Tyr Th - #r Ala Phe Gly Gly Ala 260      - #           265      - #           270 - - Thr Pro Tyr Arg Pro Ala Glu Asp Ile Ala Ph - #e Ser Val Ala Arg Phe 275          - #       280          - #       285 - - Ile Gln Asn Arg Gly Ser Leu Phe Asn Tyr Ty - #r Met Tyr His Gly Gly 290              - #   295              - #   300 - - Thr Asn Phe Gly Arg Thr Ser Asn Gly Leu Ph - #e Val Ala Thr Ser Tyr 305                 3 - #10                 3 - #15                 3 - #20 - - Asp Tyr Asp Ala Pro Ile Asp Glu Tyr Gly Le - #u Leu Asn Glu Pro Lys 325  - #               330  - #               335 - - Trp Gly His Leu Arg Glu Leu His Arg Ala Il - #e Lys Gln Cys Glu Ser 340      - #           345      - #           350 - - Ala Leu Val Ser Val Asp Pro Thr Val Ser Tr - #p Pro Gly Lys Asn Leu 355          - #       360          - #       365 - - Glu Val His Leu Tyr Lys Thr Glu Ser Ala Cy - #s Ala Ala Phe Leu Ala 370              - #   375              - #   380 - - Asn Tyr Asn Thr Asp Tyr Ser Thr Gln Val Ly - #s Phe Gly Asn Gly Gln 385                 3 - #90                 3 - #95                 4 - #00 - - Tyr Asp Leu Pro Pro Trp Ser Ile Ser Ile Le - #u Pro Asp Cys Lys Thr 405  - #               410  - #               415 - - Glu Val Phe Asn Thr Ala Lys Val Asn Ser Pr - #o Arg Leu His Arg Lys 420      - #           425      - #           430 - - Met Thr Pro Val Asn Ser Ala Phe Ala Trp Gl - #n Ser Tyr Asn Glu Glu 435          - #       440          - #       445 - - Pro Ala Ser Ser Ser Glu Asn Asp Pro Val Th - #r Gly Tyr Ala Leu Trp 450              - #   455              - #   460 - - Glu Gln Val Gly Val Thr Arg Asp Ser Ser As - #p Tyr Leu Trp Tyr Leu 465                 4 - #70                 4 - #75                 4 - #80 - - Thr Asp Val Asn Ile Gly Pro Asn Asp Ile Ly - #s Asp Gly Lys Trp Pro 485  - #               490  - #               495 - - Val Leu Thr Ala Met Ser Ala Gly His Val Le - #u Asn Val Phe Ile Asn 500      - #           505      - #           510 - - Gly Gln Tyr Ala Gly Thr Ala Tyr Gly Ser Le - #u Asp Asp Pro Arg Leu 515          - #       520          - #       525 - - Thr Phe Ser Gln Ser Val Asn Leu Arg Val Gl - #y Asn Asn Lys Ile Ser 530              - #   535              - #   540 - - Leu Leu Ser Val Ser Val Gly Leu Ala Asn Va - #l Gly Thr His Phe Glu 545                 5 - #50                 5 - #55                 5 - #60 - - Thr Trp Asn Thr Gly Val Leu Gly Pro Val Th - #r Leu Thr Gly Leu Ser 565  - #               570  - #               575 - - Ser Gly Thr Trp Asp Leu Ser Lys Gln Lys Tr - #p Ser Tyr Lys Ile Gly 580      - #           585      - #           590 - - Leu Lys Gly Glu Ser Leu Ser Leu His Thr Gl - #u Ala Gly Ser Asn Ser 595          - #       600          - #       605 - - Val Glu Trp Val Gln Gly Ser Leu Val Ala Ly - #s Lys Gln Pro Leu Ala 610              - #   615              - #   620 - - Trp Tyr Lys Thr Thr Phe Ser Ala Pro Ala Gl - #y Asn Asp Pro Leu Ala 625                 6 - #30                 6 - #35                 6 - #40 - - Leu Asp Leu Gly Ser Met Gly Lys Gly Glu Va - #l Trp Val Asn Gly Gln 645  - #               650  - #               655 - - Ser Ile Gly Arg His Trp Pro Gly Asn Lys Al - #a Arg Gly Asn Cys Gly 660      - #           665      - #           670 - - Asn Cys Asn Tyr Ala Gly Thr Tyr Thr Asp Th - #r Lys Cys Leu Ala Asn 675          - #       680          - #       685 - - Cys Gly Gln Pro Ser Gln Arg Trp Tyr His Va - #l Pro Arg Ser Trp Leu 690              - #   695              - #   700 - - Arg Ser Gly Gly Asn Tyr Leu Val Val Leu Gl - #u Glu Trp Gly Gly Asp 705                 7 - #10                 7 - #15                 7 - #20 - - Pro Asn Gly Ile Ala Leu Val Glu Arg Thr 725  - #               730 - -  - - (2) INFORMATION FOR SEQ ID NO: 3: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #3: - - Ser Val Thr Tyr Asp His Lys Ala Ile Met Il - #e Asn Gly Gln Arg Arg 1               5   - #                10  - #                15 - - Leu Ile Ser - -  - - (2) INFORMATION FOR SEQ ID NO: 4: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #4: - - Ser Val Thr Tyr Asp His Lys Ala Ile Met Il - #e Asn 1               5   - #                10 - -  - - (2) INFORMATION FOR SEQ ID NO: 5: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #5: - - Val Ala Lys Lys Gln Pro Leu Ala Trp Tyr 1               5   - #                10 - -  - - (2) INFORMATION FOR SEQ ID NO: 6: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #6: - - ATCATDATNG CYTTRTGRTC RTA           - #                  - # 23 - -  - - (2) INFORMATION FOR SEQ ID NO: 7: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #7: - - Val Ala Lys Lys Gln Pro Leu Ala Trp Tyr Ly - #s Thr Thr 1               5   - #                10 - -  - - (2) INFORMATION FOR SEQ ID NO: 8: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: internal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #8: - - Phe Ser Ala Pro Ala Gly Asn Asp Pro Leu 1               5   - #                10 - -  - - (2) INFORMATION FOR SEQ ID NO: 9: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: internal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #9: - - Gly Glu Val Trp Val Asn Gly Gln Ser Ile Gl - #y 1               5   - #                10 - -  - - (2) INFORMATION FOR SEQ ID NO: 10: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: internal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #10: - - Gly Asn Cys Gly Asn Cys Asn Tyr Ala Gly Th - #r Tyr Thr Asp Thr Lys 1               5   - #                10  - #                15 - -  - - (2) INFORMATION FOR SEQ ID NO: 11: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #11: - - Ser Val Ser Tyr Asp Asp Arg Ala Ile 1               5 - -  - - (2) INFORMATION FOR SEQ ID NO: 12: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: peptide - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -      (v) FRAGMENT TYPE: N-terminal - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #12: - - Phe Ser Asn Asn Asn Phe Val Ala Thr Asp Gl - #y Thr His Phe Ala Leu 1               5   - #                10  - #                15 - - Asn Gly Lys Ser 20 - -  - - (2) INFORMATION FOR SEQ ID NO: 13: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION:  /desc - # = "synthetic oligonucleotide" - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #13: - - ACTCCTGGAT CCCGTCAGTA T           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO: 14: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION:  /desc - # = "synthetic oligonucleotide" - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #14: - - TAATGGTACC GACCGGCGCT CT           - #                  - # 22 - -  - - (2) INFORMATION FOR SEQ ID NO: 15: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION:  /desc - # = "synthetic oligonucleotide" - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #15: - - AAGGATCCGT CGACATC             - #                  - # - #   17 - -  - - (2) INFORMATION FOR SEQ ID NO: 16: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION:  /desc - # = "synthetic oligonucleotide" - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #16: - - AAGGATCCGT CGACATCGAT AATACGACTC ACTATAGGGA TTTTTTTTTT TT - #TTTTT 57 - -  - - (2) INFORMATION FOR SEQ ID NO: 17: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION:  /desc - # = "synthetic oligonucleotide" - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #17: - - GACATCGATA ATACGAC             - #                  - # - #   17 - -  - - (2) INFORMATION FOR SEQ ID NO: 18: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2944 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: cDNA - -    (iii) HYPOTHETICAL: NO - -     (iv) ANTI-SENSE: NO - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:42..2555 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #18: - - TTAAAAAGGC ACAATCTTGA TAGAAAAGGA GATAATTTTA C ATG GGT - #TGT ACG 53 - #                  - #          Met Gly Cys Thr - - CTT ATA CTA ATG TTG AAT GTG TTG TTG GTG TT - #G TTG GGT TCA TGG GTT 101 Leu Ile Leu Met Leu Asn Val Leu Leu Val Le - #u Leu Gly Ser Trp Val 735                 7 - #40                 7 - #45                 7 - #50 - - TTT TCT GGA ACA GCT TCT GTT TCA TAT GAC CA - #T AGG GCT ATT ATT GTA      149 Phe Ser Gly Thr Ala Ser Val Ser Tyr Asp Hi - #s Arg Ala Ile Ile Val 755  - #               760  - #               765 - - AAT GGA CAA AGA AGA ATA CTT ATT TCT GGT TC - #T GTT CAT TAT CCA AGA 197 Asn Gly Gln Arg Arg Ile Leu Ile Ser Gly Se - #r Val His Tyr Pro Arg 770      - #           775      - #           780 - - AGC ACT CCT GAG ATG TGG CCA GGT ATT ATT CA - #A AAG GCT AAA GAA GGA 245 Ser Thr Pro Glu Met Trp Pro Gly Ile Ile Gl - #n Lys Ala Lys Glu Gly 785          - #       790          - #       795 - - GGT GTG GAT GTG ATT CAG ACT TAT GTT TTC TG - #G AAT GGA CAT GAG CCT 293 Gly Val Asp Val Ile Gln Thr Tyr Val Phe Tr - #p Asn Gly His Glu Pro 800              - #   805              - #   810 - - CAA CAA GGG AAA TAT TAT TTT GAA GGG AGA TA - #T GAT TTA GTG AAG TTT 341 Gln Gln Gly Lys Tyr Tyr Phe Glu Gly Arg Ty - #r Asp Leu Val Lys Phe 815                 8 - #20                 8 - #25                 8 - #30 - - ATT AAG CTG GTG CAC CAA GCA GGA CTT TAT GT - #C CAT CTT AGA GTT GGA      389 Ile Lys Leu Val His Gln Ala Gly Leu Tyr Va - #l His Leu Arg Val Gly 835  - #               840  - #               845 - - CCT TAT GCT TGT GCT GAA TGG AAT TTT GGG GG - #C TTT CCT GTT TGG CTG 437 Pro Tyr Ala Cys Ala Glu Trp Asn Phe Gly Gl - #y Phe Pro Val Trp Leu 850      - #           855      - #           860 - - AAA TAT GTT CCA GGT ATC AGT TTC AGA ACA GA - #T AAT GGA CCT TTC AAG 485 Lys Tyr Val Pro Gly Ile Ser Phe Arg Thr As - #p Asn Gly Pro Phe Lys 865          - #       870          - #       875 - - GCT GCA ATG CAA AAA TTT ACT GCC AAG ATT GT - #C AAT ATG ATG AAA GCG 533 Ala Ala Met Gln Lys Phe Thr Ala Lys Ile Va - #l Asn Met Met Lys Ala 880              - #   885              - #   890 - - GAA CGT TTG TAT GAA ACT CAA GGG GGG CCA AT - #A ATT TTA TCT CAG ATT 581 Glu Arg Leu Tyr Glu Thr Gln Gly Gly Pro Il - #e Ile Leu Ser Gln Ile 895                 9 - #00                 9 - #05                 9 - #10 - - GAG AAT GAA TAT GGA CCC ATG GAA TGG GAA CT - #G GGA GCA CCA GGT AAA      629 Glu Asn Glu Tyr Gly Pro Met Glu Trp Glu Le - #u Gly Ala Pro Gly Lys 915  - #               920  - #               925 - - TCT TAC GCA CAG TGG GCC GCC AAA ATG GCT GT - #G GGT CTT GAC ACT GGT 677 Ser Tyr Ala Gln Trp Ala Ala Lys Met Ala Va - #l Gly Leu Asp Thr Gly 930      - #           935      - #           940 - - GTC CCA TGG GTT ATG TGC AAG CAA GAC GAT GC - #C CCT GAT CCT ATT ATA 725 Val Pro Trp Val Met Cys Lys Gln Asp Asp Al - #a Pro Asp Pro Ile Ile 945          - #       950          - #       955 - - AAT GCT TGC AAT GGC TTC TAC TGT GAC TAC TT - #T TCT CCA AAC AAG GCT 773 Asn Ala Cys Asn Gly Phe Tyr Cys Asp Tyr Ph - #e Ser Pro Asn Lys Ala 960              - #   965              - #   970 - - TAT AAA CCA AAG ATA TGG ACT GAA GCC TGG AC - #T GCA TGG TTT ACT GGT 821 Tyr Lys Pro Lys Ile Trp Thr Glu Ala Trp Th - #r Ala Trp Phe Thr Gly 975                 9 - #80                 9 - #85                 9 - #90 - - TTT GGA AAT CCA GTT CCT TAC CGT CCT GCT GA - #G GAC TTG GCA TTT TCT      869 Phe Gly Asn Pro Val Pro Tyr Arg Pro Ala Gl - #u Asp Leu Ala Phe Ser 995  - #               1000  - #              1005 - - GTT GCA AAA TTT ATA CAG AAG GGA GGT TCC TT - #C ATC AAT TAT TAC ATG 917 Val Ala Lys Phe Ile Gln Lys Gly Gly Ser Ph - #e Ile Asn Tyr Tyr Met 1010     - #           1015      - #          1020 - - TAT CAT GGA GGA ACA AAC TTT GGA CGG ACT GC - #T GGT GGT CCA TTT ATT 965 Tyr His Gly Gly Thr Asn Phe Gly Arg Thr Al - #a Gly Gly Pro Phe Ile 1025         - #       1030          - #      1035 - - GCT ACT AGT TAT GAC TAT GAT GCA CCA CTT GA - #T GAA TAT GGA TTA TTG 1013 Ala Thr Ser Tyr Asp Tyr Asp Ala Pro Leu As - #p Glu Tyr Gly Leu Leu 1040             - #   1045              - #  1050 - - CGA CAA CCA AAA TGG GGT CAC CTG AAA GAT CT - #G CAT AGA GCA ATA AAG 1061 Arg Gln Pro Lys Trp Gly His Leu Lys Asp Le - #u His Arg Ala Ile Lys 1055                1060 - #                1065 - #               1070 - - CTT TGT GAA CCA GCT TTA GTC TCT GGA GAT CC - #A GCT GTG ACA GCA CTT 1109 Leu Cys Glu Pro Ala Leu Val Ser Gly Asp Pr - #o Ala Val Thr Ala Leu 1075 - #               1080  - #              1085 - - GGA CAC CAG CAG GAG GCC CAT GTT TTT AGG TC - #G AAG GCT GGC TCT TGT 1157 Gly His Gln Gln Glu Ala His Val Phe Arg Se - #r Lys Ala Gly Ser Cys 1090     - #           1095      - #          1100 - - GCT GCA TTC CTT GCT AAC TAC GAC CAA CAC TC - #T TTT GCT ACT GTG TCA 1205 Ala Ala Phe Leu Ala Asn Tyr Asp Gln His Se - #r Phe Ala Thr Val Ser 1105         - #       1110          - #      1115 - - TTT GCA AAC AGG CAT TAC AAC TTG CCA CCA TG - #G TCA ATC AGC ATT CTT 1253 Phe Ala Asn Arg His Tyr Asn Leu Pro Pro Tr - #p Ser Ile Ser Ile Leu 1120             - #   1125              - #  1130 - - CCC GAC TGC AAG AAC ACT GTA TTT AAT ACA GC - #A CGG ATC GGT GCT CAA 1301 Pro Asp Cys Lys Asn Thr Val Phe Asn Thr Al - #a Arg Ile Gly Ala Gln 1135                1140 - #                1145 - #               1150 - - AGT GCT CAG ATG AAG ATG ACT CCA GTC AGC AG - #A GGA TTG CCC TGG CAG 1349 Ser Ala Gln Met Lys Met Thr Pro Val Ser Ar - #g Gly Leu Pro Trp Gln 1155 - #               1160  - #              1165 - - TCA TTC AAT GAA GAG ACA TCA TCT TAT GAA GA - #C AGT AGT TTT ACA GTT 1397 Ser Phe Asn Glu Glu Thr Ser Ser Tyr Glu As - #p Ser Ser Phe Thr Val 1170     - #           1175      - #          1180 - - GTT GGG CTA TTG GAA CAG ATA AAT ACA ACA AG - #A GAC GTG TCT GAT TAT 1445 Val Gly Leu Leu Glu Gln Ile Asn Thr Thr Ar - #g Asp Val Ser Asp Tyr 1185         - #       1190          - #      1195 - - TTG TGG TAT TCA ACA GAT GTC AAG ATT GAT TC - #A AGA GAA AAG TTT TTG 1493 Leu Trp Tyr Ser Thr Asp Val Lys Ile Asp Se - #r Arg Glu Lys Phe Leu 1200             - #   1205              - #  1210 - - AGA GGC GGA AAA TGG CCT TGG CTT ACG ATC AT - #G TCA GCT GGG CAT GCA 1541 Arg Gly Gly Lys Trp Pro Trp Leu Thr Ile Me - #t Ser Ala Gly His Ala 1215                1220 - #                1225 - #               1230 - - TTG CAT GTT TTT GTG AAT GGT CAA TTA GCA GG - #A ACT GCA TAT GGA AGT 1589 Leu His Val Phe Val Asn Gly Gln Leu Ala Gl - #y Thr Ala Tyr Gly Ser 1235 - #               1240  - #              1245 - - TTA GAA AAA CCG AAA CTA ACT TTC AGT AAA GC - #C GTA AAT CTG AGA GCA 1637 Leu Glu Lys Pro Lys Leu Thr Phe Ser Lys Al - #a Val Asn Leu Arg Ala 1250     - #           1255      - #          1260 - - GGT GTT AAC AAG ATT TCT CTA CTG AGC ATT GC - #T GTT GGC CTT CCG AAT 1685 Gly Val Asn Lys Ile Ser Leu Leu Ser Ile Al - #a Val Gly Leu Pro Asn 1265         - #       1270          - #      1275 - - ATC GGC CCA CAT TTT GAG ACA TGG AAT GCT GG - #T GTT CTT GGG CCA GTC 1733 Ile Gly Pro His Phe Glu Thr Trp Asn Ala Gl - #y Val Leu Gly Pro Val 1280             - #   1285              - #  1290 - - TCA CTA ACT GGT CTT GAC GAG GGG AAA AGA GA - #T TTA ACA TGG CAG AAA 1781 Ser Leu Thr Gly Leu Asp Glu Gly Lys Arg As - #p Leu Thr Trp Gln Lys 1295                1300 - #                1305 - #               1310 - - TGG TTC TAC AAG GTT GGT CTA AAA GGA GAA GC - #C CTG AGT CTT CAT TCA 1829 Trp Phe Tyr Lys Val Gly Leu Lys Gly Glu Al - #a Leu Ser Leu His Ser 1315 - #               1320  - #              1325 - - CTC AGT GGT AGC CCA TCC GTG GAG TGG GTG GA - #A GGC TCT TTA GTG GCA 1877 Leu Ser Gly Ser Pro Ser Val Glu Trp Val Gl - #u Gly Ser Leu Val Ala 1330     - #           1335      - #          1340 - - CAG AAG CAG CCA CTC AGT TGG TAT AAG ACT AC - #A TTC AAT GCT CCA GAT 1925 Gln Lys Gln Pro Leu Ser Trp Tyr Lys Thr Th - #r Phe Asn Ala Pro Asp 1345         - #       1350          - #      1355 - - GGA AAT GAA CCT TTG GCT TTA GAT ATG AAT AC - #C ATG GGC AAA GGT CAA 1973 Gly Asn Glu Pro Leu Ala Leu Asp Met Asn Th - #r Met Gly Lys Gly Gln 1360             - #   1365              - #  1370 - - GTA TGG ATA AAT GGT CAG AGC CTC GGA CGC CA - #C TGG CCT GCA TAT AAA 2021 Val Trp Ile Asn Gly Gln Ser Leu Gly Arg Hi - #s Trp Pro Ala Tyr Lys 1375                1380 - #                1385 - #               1390 - - TCA TCT GGA AGT TGT AGT GTC TGT AAC TAT AC - #T GGC TGG TTT GAT GAG 2069 Ser Ser Gly Ser Cys Ser Val Cys Asn Tyr Th - #r Gly Trp Phe Asp Glu 1395 - #               1400  - #              1405 - - AAA AAG TGC CTA ACT AAC TGT GGT GAG GGC TC - #A CAA AGA TGG TAC CAC 2117 Lys Lys Cys Leu Thr Asn Cys Gly Glu Gly Se - #r Gln Arg Trp Tyr His 1410     - #           1415      - #          1420 - - GTA CCC CGG TCT TGG CTG TAT CCT ACT GGA AA - #T TTG TTA GTT GTA TTC 2165 Val Pro Arg Ser Trp Leu Tyr Pro Thr Gly As - #n Leu Leu Val Val Phe 1425         - #       1430          - #      1435 - - GAG GAA TGG GGA GGA GAT CCT TAT GGA ATC AC - #T TTA GTC AAA AGA GAA 2213 Glu Glu Trp Gly Gly Asp Pro Tyr Gly Ile Th - #r Leu Val Lys Arg Glu 1440             - #   1445              - #  1450 - - ATA GGG AGT GTT TGT GCT GAT ATA TAT GAG TG - #G CAA CCA CAG TTA TTG 2261 Ile Gly Ser Val Cys Ala Asp Ile Tyr Glu Tr - #p Gln Pro Gln Leu Leu 1455                1460 - #                1465 - #               1470 - - AAT TGG CAG AGG CTA GTA TCT GGT AAG TTT GA - #C AGA CCT CTC AGA CCT 2309 Asn Trp Gln Arg Leu Val Ser Gly Lys Phe As - #p Arg Pro Leu Arg Pro 1475 - #               1480  - #              1485 - - AAA GCC CAT CTT AAG TGT GCA CCT GGT CAG AA - #G ATT TCT TCA ATC AAA 2357 Lys Ala His Leu Lys Cys Ala Pro Gly Gln Ly - #s Ile Ser Ser Ile Lys 1490     - #           1495      - #          1500 - - TTT GCA AGC TTT GGA ACA CCA GAG GGA GTT TG - #T GGG AAC TTC CAG CAG 2405 Phe Ala Ser Phe Gly Thr Pro Glu Gly Val Cy - #s Gly Asn Phe Gln Gln 1505         - #       1510          - #      1515 - - GGA AGC TGC CAT GCT CCG CGC TCA TAT GAT GC - #T TTC AAA AAG AAT TGT 2453 Gly Ser Cys His Ala Pro Arg Ser Tyr Asp Al - #a Phe Lys Lys Asn Cys 1520             - #   1525              - #  1530 - - GTT GGG AAA GAG TCT TGC TCA GTA CAG GTA AC - #A CCA GAG AAT TTT GGA 2501 Val Gly Lys Glu Ser Cys Ser Val Gln Val Th - #r Pro Glu Asn Phe Gly 1535                1540 - #                1545 - #               1550 - - GGT GAT CCA TGT CGA AAC GTT CTA AAG AAA CT - #C TCA GTG GAA GCC ATT 2549 Gly Asp Pro Cys Arg Asn Val Leu Lys Lys Le - #u Ser Val Glu Ala Ile 1555 - #               1560  - #              1565 - - TGT AGT TGATAATTCT GAGTATACAA GTGAAAAAAT ACTTGAACCA CT - #CATATAAA 2605 Cys Ser - - CATTTTTCAA ACGAGCTACT AGACATCCAT TAACCCACAC TACCATTTTT TG - #GCTTTGCT   2665 - - GGGGTTGAAG TTGTACAGTT AAGCAACACA CCTCTTTGAT CAAAGCTCAC CT - #GATTATGA   2725 - - AGATGATTGA CGAAAGATTC TGTACATGTA AGGTTTCGTC TAATTACACA TA - #CAGATATG   2785 - - ATTCTTGATG AATCGATGTG CAAATTTTGT TTGTGTTAGG GTGAGAGAGA CT - #TGAAAAGC   2845 - - ATTTTGCTTT CATGATGTTC TACATTATAC AATCATAATG TAAGTAAGCA AG - #CAATAATT   2905 - - CATTGCTTTG CACATTGAAA AAAAAAAAAA AAAAAAAAA      - # - #  2944 - -  - - (2) INFORMATION FOR SEQ ID NO: 19: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 838 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #19: - - Met Gly Cys Thr Leu Ile Leu Met Leu Asn Va - #l Leu Leu Val Leu Leu 1               5 - #                 10 - #                 15 - - Gly Ser Trp Val Phe Ser Gly Thr Ala Ser Va - #l Ser Tyr Asp His Arg 20     - #             25     - #             30 - - Ala Ile Ile Val Asn Gly Gln Arg Arg Ile Le - #u Ile Ser Gly Ser Val 35         - #         40         - #         45 - - His Tyr Pro Arg Ser Thr Pro Glu Met Trp Pr - #o Gly Ile Ile Gln Lys 50             - #     55             - #     60 - - Ala Lys Glu Gly Gly Val Asp Val Ile Gln Th - #r Tyr Val Phe Trp Asn 65                 - # 70                 - # 75                 - # 80 - - Gly His Glu Pro Gln Gln Gly Lys Tyr Tyr Ph - #e Glu Gly Arg Tyr Asp 85 - #                 90 - #                 95 - - Leu Val Lys Phe Ile Lys Leu Val His Gln Al - #a Gly Leu Tyr Val His 100      - #           105      - #           110 - - Leu Arg Val Gly Pro Tyr Ala Cys Ala Glu Tr - #p Asn Phe Gly Gly Phe 115          - #       120          - #       125 - - Pro Val Trp Leu Lys Tyr Val Pro Gly Ile Se - #r Phe Arg Thr Asp Asn 130              - #   135              - #   140 - - Gly Pro Phe Lys Ala Ala Met Gln Lys Phe Th - #r Ala Lys Ile Val Asn 145                 1 - #50                 1 - #55                 1 - #60 - - Met Met Lys Ala Glu Arg Leu Tyr Glu Thr Gl - #n Gly Gly Pro Ile Ile 165  - #               170  - #               175 - - Leu Ser Gln Ile Glu Asn Glu Tyr Gly Pro Me - #t Glu Trp Glu Leu Gly 180      - #           185      - #           190 - - Ala Pro Gly Lys Ser Tyr Ala Gln Trp Ala Al - #a Lys Met Ala Val Gly 195          - #       200          - #       205 - - Leu Asp Thr Gly Val Pro Trp Val Met Cys Ly - #s Gln Asp Asp Ala Pro 210              - #   215              - #   220 - - Asp Pro Ile Ile Asn Ala Cys Asn Gly Phe Ty - #r Cys Asp Tyr Phe Ser 225                 2 - #30                 2 - #35                 2 - #40 - - Pro Asn Lys Ala Tyr Lys Pro Lys Ile Trp Th - #r Glu Ala Trp Thr Ala 245  - #               250  - #               255 - - Trp Phe Thr Gly Phe Gly Asn Pro Val Pro Ty - #r Arg Pro Ala Glu Asp 260      - #           265      - #           270 - - Leu Ala Phe Ser Val Ala Lys Phe Ile Gln Ly - #s Gly Gly Ser Phe Ile 275          - #       280          - #       285 - - Asn Tyr Tyr Met Tyr His Gly Gly Thr Asn Ph - #e Gly Arg Thr Ala Gly 290              - #   295              - #   300 - - Gly Pro Phe Ile Ala Thr Ser Tyr Asp Tyr As - #p Ala Pro Leu Asp Glu 305                 3 - #10                 3 - #15                 3 - #20 - - Tyr Gly Leu Leu Arg Gln Pro Lys Trp Gly Hi - #s Leu Lys Asp Leu His 325  - #               330  - #               335 - - Arg Ala Ile Lys Leu Cys Glu Pro Ala Leu Va - #l Ser Gly Asp Pro Ala 340      - #           345      - #           350 - - Val Thr Ala Leu Gly His Gln Gln Glu Ala Hi - #s Val Phe Arg Ser Lys 355          - #       360          - #       365 - - Ala Gly Ser Cys Ala Ala Phe Leu Ala Asn Ty - #r Asp Gln His Ser Phe 370              - #   375              - #   380 - - Ala Thr Val Ser Phe Ala Asn Arg His Tyr As - #n Leu Pro Pro Trp Ser 385                 3 - #90                 3 - #95                 4 - #00 - - Ile Ser Ile Leu Pro Asp Cys Lys Asn Thr Va - #l Phe Asn Thr Ala Arg 405  - #               410  - #               415 - - Ile Gly Ala Gln Ser Ala Gln Met Lys Met Th - #r Pro Val Ser Arg Gly 420      - #           425      - #           430 - - Leu Pro Trp Gln Ser Phe Asn Glu Glu Thr Se - #r Ser Tyr Glu Asp Ser 435          - #       440          - #       445 - - Ser Phe Thr Val Val Gly Leu Leu Glu Gln Il - #e Asn Thr Thr Arg Asp 450              - #   455              - #   460 - - Val Ser Asp Tyr Leu Trp Tyr Ser Thr Asp Va - #l Lys Ile Asp Ser Arg 465                 4 - #70                 4 - #75                 4 - #80 - - Glu Lys Phe Leu Arg Gly Gly Lys Trp Pro Tr - #p Leu Thr Ile Met Ser 485  - #               490  - #               495 - - Ala Gly His Ala Leu His Val Phe Val Asn Gl - #y Gln Leu Ala Gly Thr 500      - #           505      - #           510 - - Ala Tyr Gly Ser Leu Glu Lys Pro Lys Leu Th - #r Phe Ser Lys Ala Val 515          - #       520          - #       525 - - Asn Leu Arg Ala Gly Val Asn Lys Ile Ser Le - #u Leu Ser Ile Ala Val 530              - #   535              - #   540 - - Gly Leu Pro Asn Ile Gly Pro His Phe Glu Th - #r Trp Asn Ala Gly Val 545                 5 - #50                 5 - #55                 5 - #60 - - Leu Gly Pro Val Ser Leu Thr Gly Leu Asp Gl - #u Gly Lys Arg Asp Leu 565  - #               570  - #               575 - - Thr Trp Gln Lys Trp Phe Tyr Lys Val Gly Le - #u Lys Gly Glu Ala Leu 580      - #           585      - #           590 - - Ser Leu His Ser Leu Ser Gly Ser Pro Ser Va - #l Glu Trp Val Glu Gly 595          - #       600          - #       605 - - Ser Leu Val Ala Gln Lys Gln Pro Leu Ser Tr - #p Tyr Lys Thr Thr Phe 610              - #   615              - #   620 - - Asn Ala Pro Asp Gly Asn Glu Pro Leu Ala Le - #u Asp Met Asn Thr Met 625                 6 - #30                 6 - #35                 6 - #40 - - Gly Lys Gly Gln Val Trp Ile Asn Gly Gln Se - #r Leu Gly Arg His Trp 645  - #               650  - #               655 - - Pro Ala Tyr Lys Ser Ser Gly Ser Cys Ser Va - #l Cys Asn Tyr Thr Gly 660      - #           665      - #           670 - - Trp Phe Asp Glu Lys Lys Cys Leu Thr Asn Cy - #s Gly Glu Gly Ser Gln 675          - #       680          - #       685 - - Arg Trp Tyr His Val Pro Arg Ser Trp Leu Ty - #r Pro Thr Gly Asn Leu 690              - #   695              - #   700 - - Leu Val Val Phe Glu Glu Trp Gly Gly Asp Pr - #o Tyr Gly Ile Thr Leu 705                 7 - #10                 7 - #15                 7 - #20 - - Val Lys Arg Glu Ile Gly Ser Val Cys Ala As - #p Ile Tyr Glu Trp Gln 725  - #               730  - #               735 - - Pro Gln Leu Leu Asn Trp Gln Arg Leu Val Se - #r Gly Lys Phe Asp Arg 740      - #           745      - #           750 - - Pro Leu Arg Pro Lys Ala His Leu Lys Cys Al - #a Pro Gly Gln Lys Ile 755          - #       760          - #       765 - - Ser Ser Ile Lys Phe Ala Ser Phe Gly Thr Pr - #o Glu Gly Val Cys Gly 770              - #   775              - #   780 - - Asn Phe Gln Gln Gly Ser Cys His Ala Pro Ar - #g Ser Tyr Asp Ala Phe 785                 7 - #90                 7 - #95                 8 - #00 - - Lys Lys Asn Cys Val Gly Lys Glu Ser Cys Se - #r Val Gln Val Thr Pro 805  - #               810  - #               815 - - Glu Asn Phe Gly Gly Asp Pro Cys Arg Asn Va - #l Leu Lys Lys Leu Ser 820      - #           825      - #           830 - - Val Glu Ala Ile Cys Ser 835 - -  - - (2) INFORMATION FOR SEQ ID NO: 20: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 731 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO: - #20: - - Met Leu Cys Gly Lys Glu Asn Asn Val Met Ly - #s Met Met Leu Val Tyr 1               5 - #                 10 - #                 15 - - Val Phe Val Leu Ile Thr Leu Ile Ser Cys Va - #l Tyr Gly Asn Val Trp 20     - #             25     - #             30 - - Tyr Asp Tyr Arg Ala Ile Lys Ile Asn Asp Gl - #n Arg Arg Ile Leu Leu 35         - #         40         - #         45 - - Ser Gly Ser Ile His Tyr Pro Arg Ser Thr Pr - #o Glu Met Trp Pro Asp 50             - #     55             - #     60 - - Ile Ile Glu Lys Ala Lys Asp Ser Gln Leu As - #p Val Ile Gln Thr Tyr 65                 - # 70                 - # 75                 - # 80 - - Val Phe Trp Asn Gly His Glu Pro Ser Glu Gl - #y Lys Tyr Tyr Phe Glu 85 - #                 90 - #                 95 - - Gly Arg Tyr Asp Leu Val Lys Phe Ile Lys Le - #u Ile His Gln Ala Gly 100      - #           105      - #           110 - - Leu Phe Val His Leu Arg Ile Gly Pro Phe Al - #a Cys Ala Glu Trp Asn 115          - #       120          - #       125 - - Phe Gly Gly Phe Pro Val Trp Leu Lys Tyr Va - #l Pro Gly Ile Glu Phe 130              - #   135              - #   140 - - Arg Thr Asp Asn Gly Pro Phe Lys Glu Lys Me - #t Gln Val Phe Thr Thr 145                 1 - #50                 1 - #55                 1 - #60 - - Lys Ile Val Asp Met Met Lys Ala Glu Lys Le - #u Phe His Trp Gln Gly 165  - #               170  - #               175 - - Gly Pro Ile Ile Leu Asn Gln Ile Glu Asn Gl - #u Tyr Gly Pro Val Glu 180      - #           185      - #           190 - - Trp Glu Ile Gly Ala Pro Gly Lys Ala Tyr Th - #r His Trp Ala Ala Gln 195          - #       200          - #       205 - - Met Ala Gln Ser Leu Asn Ala Gly Val Pro Tr - #p Ile Met Cys Lys Gln 210              - #   215              - #   220 - - Asp Ser Asp Val Pro Asp Asn Val Ile Asp Th - #r Cys Asn Gly Phe Tyr 225                 2 - #30                 2 - #35                 2 - #40 - - Cys Glu Gly Phe Val Pro Lys Asp Lys Ser Ly - #s Pro Lys Met Trp Thr 245  - #               250  - #               255 - - Glu Asn Trp Thr Gly Trp Tyr Thr Glu Tyr Gl - #y Lys Pro Val Pro Tyr 260      - #           265      - #           270 - - Arg Pro Ala Glu Asp Val Ala Phe Ser Val Al - #a Arg Phe Ile Gln Asn 275          - #       280          - #       285 - - Gly Gly Ser Phe Met Asn Tyr Tyr Met Phe Hi - #s Gly Gly Thr Asn Phe 290              - #   295              - #   300 - - Glu Thr Thr Ala Gly Arg Phe Val Ser Thr Se - #r Tyr Asp Tyr Asp Ala 305                 3 - #10                 3 - #15                 3 - #20 - - Pro Leu Asp Glu Tyr Gly Leu Pro Arg Glu Pr - #o Lys Tyr Thr His Leu 325  - #               330  - #               335 - - Lys Asn Leu His Lys Ala Ile Lys Met Cys Gl - #u Pro Ala Leu Val Ser 340      - #           345      - #           350 - - Ser Asp Ala Lys Val Thr Asn Leu Gly Ser As - #n Gln Glu Ala His Val 355          - #       360          - #       365 - - Tyr Ser Ser Asn Ser Gly Ser Cys Ala Ala Ph - #e Leu Ala Asn Tyr Asp 370              - #   375              - #   380 - - Pro Lys Trp Ser Val Lys Val Thr Phe Ser Gl - #y Met Glu Phe Glu Leu 385                 3 - #90                 3 - #95                 4 - #00 - - Pro Ala Trp Ser Ile Ser Ile Leu Pro Asp Cy - #s Lys Lys Glu Val Tyr 405  - #               410  - #               415 - - Asn Thr Ala Arg Val Asn Glu Pro Ser Pro Ly - #s Leu His Ser Lys Met 420      - #           425      - #           430 - - Thr Pro Val Ile Ser Asn Leu Asn Trp Gln Se - #r Tyr Ser Asp Glu Val 435          - #       440          - #       445 - - Pro Thr Ala Asp Ser Pro Gly Thr Phe Arg Gl - #u Lys Lys Leu Tyr Glu 450              - #   455              - #   460 - - Gln Ile Asn Met Thr Trp Asp Lys Ser Asp Ty - #r Leu Trp Tyr Met Thr 465                 4 - #70                 4 - #75                 4 - #80 - - Asp Val Val Leu Asp Gly Asn Glu Gly Phe Le - #u Lys Lys Gly Asp Glu 485  - #               490  - #               495 - - Pro Trp Leu Thr Val Asn Ser Ala Gly His Va - #l Leu His Val Phe Val 500      - #           505      - #           510 - - Asn Gly Gln Leu Gln Gly His Ala Tyr Gly Se - #r Leu Ala Lys Pro Gln 515          - #       520          - #       525 - - Leu Thr Phe Ser Gln Lys Val Lys Met Thr Al - #a Gly Val Asn Arg Ile 530              - #   535              - #   540 - - Ser Leu Leu Ser Ala Val Val Gly Leu Ala As - #n Val Gly Trp His Phe 545                 5 - #50                 5 - #55                 5 - #60 - - Glu Arg Tyr Asn Gln Gly Val Leu Gly Pro Va - #l Thr Leu Ser Gly Leu 565  - #               570  - #               575 - - Asn Glu Gly Thr Arg Asp Leu Thr Trp Gln Ty - #r Trp Ser Tyr Lys Ile 580      - #           585      - #           590 - - Gly Thr Lys Gly Glu Glu Gln Gln Val Tyr As - #n Ser Gly Gly Ser Ser 595          - #       600          - #       605 - - His Val Gln Trp Gly Pro Pro Ala Trp Lys Gl - #n Pro Leu Val Trp Tyr 610              - #   615              - #   620 - - Lys Thr Thr Phe Asp Ala Pro Gly Gly Asn As - #p Pro Leu Ala Leu Asp 625                 6 - #30                 6 - #35                 6 - #40 - - Leu Gly Ser Met Gly Lys Gly Gln Ala Trp Il - #e Asn Gly Gln Ser Ile 645  - #               650  - #               655 - - Gly Arg His Trp Ser Asn Asn Ile Ala Lys Gl - #y Ser Cys Asn Asp Asn 660      - #           665      - #           670 - - Cys Asn Tyr Ala Gly Thr Tyr Thr Glu Thr Ly - #s Cys Leu Ser Asp Cys 675          - #       680          - #       685 - - Gly Lys Ser Ser Gln Lys Trp Tyr His Val Pr - #o Arg Ser Trp Leu Gln 690              - #   695              - #   700 - - Pro Arg Gly Asn Leu Leu Val Val Phe Glu Gl - #u Trp Gly Gly Asp Thr 705                 7 - #10                 7 - #15                 7 - #20 - - Lys Trp Val Ser Leu Val Lys Arg Thr Ile Al - #a 725  - #               730 __________________________________________________________________________

## Claims

1. An isolated nucleic acid encoding an enzyme having exo-(1.fwdarw.4)-.beta.-D-galactanase activity, said enzyme comprising amino acid residues 34-730 of SEQ ID NO:2.

2. An isolated nucleic acid encoding an enzyme having exo-(1.fwdarw.4)-.beta.-D-galactanase activity, said enzyme comprising amino acid residues 26-838 of SEQ ID NO:19.

3. An isolated nucleic acid according to claim 1, comprising a nucleotide sequence selected from the group consisting of nucleotides 163-228, nucleotides 151-228, nucleotides 130-228, and nucleotides 229-2319 of SEQ ID NO:1.

4. An isolated nucleic acid according to claim 2, comprising a nucleotide sequence selected from the group consisting of nucleotides 42-2555 and nucleotides 117-2555, of SEQ ID NO:18.

5. An isolated nucleic acid according to claim 1 or 2, comprising an ATG start signal.

6. An isolated nucleic acid comprising a portion of a nucleotide sequence of SEQ ID NO:1 operably linked in the antisense orientation to a promoter, said sequence being capable of hybridizing with a nucleotide sequence of nucleotides 229-2319 of SEQ ID NO:1.

7. An isolated nucleic acid comprising a portion of a nucleotide sequence of SEQ ID NO:18 operably linked in the antisense orientation to a promoter, said sequence being capable of hybridizing with a nucleotide sequence of nucleotides 117-2555 of SEQ ID NO:18.

8. An isolated nucleic acid sequence according to claim 7, comprising a nucleotide sequence selected from the group consisting of nucleotides 419-1500 and nucleotides 1292-1802, of SEQ ID NO:18 operably linked in the antisense orientation to a promoter.

9. A vector comprising a nucleic acid according to any one of claims 1-4 capable, when introduced into a host cell, of giving rise to an RNA transcript in the host cell.

10. A vector according to claim 9 capable, when introduced into a host cell, of giving rise to a polypeptide having exo-galactanase activity.

11. A host plant or part thereof, into which has been introduced a vector according to any one of claims 6-8, having altered physical characteristics as a result of the introduction.

12. A host cell into which has been introduced a vector according to claim 9.

13. A host plant or part thereof, into which has been introduced a vector according to claim 9, having altered physical characteristics as a result of the introduction.